



LIVE Leading
LIVE Innovative
LIVE Vascular
2015 Education

Organized by:



Institute
of Vascular Diseases (IVD),
Greece

In collaboration with:



Hellenic Society
of Vascular and
Endovascular Surgery



STONY BROOK
UNIVERSITY
MEDICAL CENTER
Stony Brook University
Medical Center,
New York, USA



May 21-23
2015

<http://www.live2015.gr>

Aquila Atlantis Hotel
Heraklion Crete
GREECE

ESCVS
SUMMER SCHOOL
May 20-21, 2015

Final Programme

Table of Contents

Welcome	4
Organization	5
Guidelines for Invited Faculty & Presenting Authors	6-9
Scientific Programme	10-27
Summer School of the ESCVS	10-12
Pre-Symposium Course	13-14
Thursday, May 21, 2015	15-17
Friday, May 22, 2015	18-21
Saturday, May 23, 2015	22-27
Invited Faculty	28-37
General Information	40-44
Registration	47-48
Accreditation	49
Oral & e-Poster Presentations Sessions	51-64
Satellite Sessions	67-69
Sponsors/Acknowledgements	71

Focus on active learning!

Dear colleagues, dear friends,

It is our great pleasure to welcome you this year in Heraklion, Greece for LIVE 2015-Leading Innovative Vascular Education, the annual international meeting of the Institute of Vascular Diseases held every year in Greece. LIVE 2015 is organized in collaboration with the Hellenic Society of Vascular and Endovascular Surgery (HSVS) and the Stony Brook University, Medical Center, New York, USA.

Committed to its main aim, LIVE 2015 symposium is formed to be attractive and towards the needs of young researchers-trainees, appropriate to share knowledge and experience on current evidence. It will give participants the opportunity to learn and keep updated from world renowned experts, to contribute to an open dialogue about all up to date technology advances regarding diagnosis and management of vascular pathologies. The successful format for communication and discussion included in all sessions will help to disseminate knowledge from experienced and introduce the newcomers.

The European Society for Vascular Surgery (ESVS) embraces LIVE 2015 programme with a pre-symposium course. The programme also incorporates oral, & e-poster presentations sessions, multiple scientific sessions, lectures by experts, lunch sessions, debate with voting by the audience and special sessions for vascular nursing and vascular anaesthesia topics.

This year's Congress will also bring a new cooperation with the European Society for Cardiovascular and Endovascular Surgery (ESCVS) with the organization of the Summer School which will be held on Wednesday, May 20th and Thursday, May 21st. We hope that young participants of the Summer School will enjoy also their participation in LIVE 2015.

We cannot be but grateful to both ESVS & ESCVS administrations for their support, to all those who worked for the organization and realization of LIVE 2015, to all invited faculty, Greek and foreign.

Thank you for being here with us in Heraklion. Enjoy your stay!

LIVE 2015 Directors,
A. Giannoukas, N. Labropoulos, M. Lazarides,
M. Matsagkas, D. Tsetis, I. Tsolakis

Organized by



**Institute of Vascular Diseases,
(I.V.D.), Greece**

In collaboration with:



**Hellenic Society
of Vascular and Endovascular Surgery**



**Stony Brook University Medical Center,
New York, USA**

LIVE 2015 Directors

Athanasios Giannoukas

*Professor of Vascular Surgery, Faculty of Medicine,
School of Health Sciences, University of Thessaly, Larissa, Greece*

Nicos Labropoulos

*Professor of Surgery and Radiology, Director, Vascular Laboratory,
Department of Surgery, Stony Brook University Medical Center,
Stony Brook, New York, USA*

Miltos Lazarides

*Professor of Vascular Surgery, Faculty of Medicine, School of Health
Sciences, Democritus University of Thrace, Alexandroupolis, Greece*

Miltiadis Matsagkas

*Professor of Vascular Surgery, Faculty of Medicine,
School of Health Sciences, University of Ioannina, Greece*

Dimitrios Tsetis

*Associate Professor of Interventional Radiology, Faculty of Medicine,
School of Health Sciences, University of Crete, Heraklion, Greece*

Ioannis Tsolakis

*Professor of Vascular Surgery, Faculty of Medicine,
School of Health Sciences, University of Patras, Greece*

A. For PPT Presentations (*applies to all presenters*)

PPT Format (OPTIONAL)

All presenters were encouraged to use one of the official LIVE 2015 templates in order to provide a uniform look to their presentation.

Formal Requirements

Language: All presentations have to be given in **English** (as the official language of the symposium is English and no simultaneous translation will be provided).

Advertising: Advertising of products is **prohibited**. Be sure your slides are free of any commercial bias (eg company names or logos).

Patient anonymity: Kindly make sure that no patient names or any other information allowing the identification of a patient appear in your presentation.

Copyright reserved: It is the author's responsibility to ensure that any part of the slide show (figures, tables, images, etc.) is free of any third party right.

Technical Requirements

Preparation

Format: preferable format is MS PowerPoint (ppt or pps). *Macintosh presentations will be accepted**.

Versions: up to MS PowerPoint 2010.

Saving of files: For onsite upload, the presentation has to be saved on a USB flash (recommended), CD-ROM or DVD-ROM.

Video clips: If you are using embedded video clips in your presentation, please remember to also have the video clips in a separate file (not only in the presentation).

Fonts & character: To avoid any possible compatibility problems, it is preferable not use any special fonts or special characters.

Onsite presentation

You are kindly requested to deliver your presentation(s) to the technical support personnel at least **one (1) hour before the beginning of the Session** (in order to ensure on time they run smoothly and to be able of making any possible changes). If the presentation is scheduled early in the morning, you are kindly requested to check your presentation with the technical support personnel the day before.

Guidelines for Invited Faculty & Presenting Authors

Your PPT presentation will be made available in the lecture hall via computer network. There will be no possibility to connect your personal laptop in the lecture hall, due to very restricted timeslots (row of the presentations).

The Hall will be equipped with the following:

• LCD projector with remote control (operated by presenter-no mouse will be available) • Screen & Lighted pointer • Podium mounted microphone • Audience aisle microphones

It is very important to respect the flow of the session and the exact time available for each presentation and therefore you are requested to be consistent with the time slots. It is advisable to rehearse your presentation prior to the congress to ascertain that the **time is not exceeded**.

****To the attention of Mac users:***

Please make sure to come with the suitable adapter and to also have a backup PPT for PC.

You are kindly requested to meet with the technical support personnel at least **two (2) hours before the beginning of the session**, in order to assure compatibility (or backup solutions).

B. Time Slots (*applies to Chairmen/Moderators*)

The profile of LIVE 2015 is mainly **educational**, focusing on providing high quality continuing education by the presentation of the latest significant advances in the area of vascular diseases and encouraging the interaction and open discussion between speakers and participants.

As a chairman or Moderator, you should ensure the smooth progress of the session, time management as well as encourage discussions and interactions between faculty members and the audience by allowing sufficient time for questions from the audience.

In order to be helped, a **timer** will be running on the screen along with the presentation. After a warning (before the last minute of the presentation) the projection will be stopped and you will have to ask from the presenter to conclude.

C. Conflict of Interest Disclosure (*applies to all invited faculty*)

It is the policy of the European Accreditation Council for Continuing Medical Education (EACCME) to ensure that all Live Education Events (LEEs) that receive accreditation will be balanced, independent, objective, scientifically rigorous and in the best interest of patient care. Thus, in compliance with UEMS guidelines, speakers/chairmen participating in LIVE 2015 are **strictly requested** to disclose or indicate potential conflicts of interest (with LIVE2015 sponsors) that might cause a bias. More specifically:

(Essential criterion)

In accordance with criterion 27 of document UEMS 2012/30 "Accreditation of Live Educational Events by the EACCME", the Provider must ensure that all members of the Faculty will provide written declarations of potential or actual conflicts of interest.

These declarations must be made publicly available (either in printed form or in electronic form on the website of the organizer of the LEE). The EACCME® considers it a responsibility of the head of the Scientific and/or Organizing Committee to ensure that actual conflicts of interest are resolved. The EACCME® has provided a template, available on the EACCME® website, that provides a guide as to what information must be declared. These declarations must be retained for at least one year after the event for potential review by the EACCME®.

Therefore you **are requested (if not already done) to:**

1. Advise the LIVE2015 sponsors file
2. Declare any potential or actual conflict of interest regarding the above sponsors and topics of the presentation (s)
 - at the Second Slide of your PowerPoint Presentation (if speaker)
 - or orally at the beginning of the session (if chairman etc)
3. Complete and return the COI Disclosure Form (available at the Secretariat)

The existence of potential conflicts of interest does not necessarily indicate a bias. However it is your ethical obligation to inform organizers and participants so that they are made aware of any relationship with the sponsors that might cause unintentional bias. A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, funding for research, investments, family relationship etc.

D. PPT Presentations Publishing/Webcasting-*Permission (applies to Invited Speakers)*

According to the LIVE 2015 Directors' willingness, this year's Congress (main hall) will be recorded and broadcasted (in a second time) via the **Institute of Vascular Disease's** portal, <http://www.ivd.gr>.

Due to the importance of your presentation we would like to request for your permission to record your lecture and your presentation and broadcast it in this specific area.

Due to legal reasons, LIVE 2015 organization cannot be held responsible for any of the materials included in your presentation. It is of your responsibility to ensure that any part of the slide show (figures, tables, images, etc.) is free of any third party right (copyright permission and the right to republish scientific information). Due to the importance of your presentation, we must have your permission and you will be requested from the Technical Support Personnel to give your written permission.



Watch the congress on
<http://www.ivd.gr>

SUMMER SCHOOL OF THE ESCVS

Writing and Presenting Scientific Paper

Organized by the European Society
for Cardiovascular & Endovascular Surgery (ESCVS).

For information/registration delegates should refer to the ESCVS.

15:00-18:00 **PART I - Writing an abstract**

Moderators:

**Oztekin Oto (Turkey),
Athanasios Giannoukas (Greece),
Lazar Davidovic (Serbia)**

15:00-15:15 How do I review abstract for the annual meeting

Nicos Labropoulos (USA)

15:16-15:30 How to write an abstract for scientific meeting

Ahmet Tulga Ulus (Turkey)

15:31-15:45 *Discussion*

15:46-16:45 Participants would be separated in groups and should write abstracts from the data given by the database

Coordinators:

**Ahmet Tulga Ulus (Turkey),
Igor Koncar (Serbia),
Nicos Rousas (Greece)**

16:46-17:45 Groups should present abstracts with interactive comments

Comments: **Oztekin Oto (Turkey),
Martin Veller (South Africa),
Nicos Labropoulos (USA),
Apostolos Tassiopoulos (USA),
Antonios Gasparis (USA)**

17:46-18:00 *Discussion*

SUMMER SCHOOL OF THE ESCVS

Writing and Presenting Scientific Paper

Organized by the European Society
for Cardiovascular & Endovascular (ESCVS).

For information/registration delegates should refer to the ESCVS.

Parallel Session

- 09:00-13:00** **PART II - How to present scientific paper & reviewers' point of view**
Moderators: **Oztekin Oto (Turkey),
Lazar Davidovic (Serbia)**
- 09:00-09:15 Successful presentation in the scientific meeting
Lazar Davidovic (Serbia)
- 09:16-09:45 Participants will present their own presentations and get opinion from the experts
Panel of experts: **Janet Powell (UK),
Martin Veller (USA),
Oztekin Oto (Turkey),
Lazar Davidovic (Serbia),
Nicos Labropoulos (USA),
Ahmet Tulga Ulus (Turkey)**
- 09:45-10:00 **Break**
- 10:01-10:30 Reviewers job is to criticize or improve paper - take the reviewers point of view
Janet Powell (UK)
- 10:31-12:00 Participants would be separated in groups and review preselected papers
Coordinators: **Igor Koncar (Serbia),
Nicos Rousas (Greece)**
- 12:01-13:00 Reviews will be presented and discussed
Panel of experts:
**Janet Powell (UK),
Martin Veller (USA),
Oztekin Oto (Turkey),
Lazar Davidovic (Serbia),
Nicos Labropoulos (USA),
Ahmet Tulga Ulus (Turkey),
Athanasios Giannoukas (Greece),
Miltiadis Matsagkas (Greece)**
- 13:00-16:00 **Leisure time**

SUMMER SCHOOL OF THE ESCVS
Writing and Presenting Scientific Paper

*Organized by the European Society
for Cardiovascular & Endovascular Surgery (ESCVS).*

For information/registration delegates should refer to the ESCVS.

Parallel Session

16:00-19:00 **PART III - Seminar on Thrombosis and Antithrombotic Treatment**
Moderators: **Miltiadis Matsagkas (Greece),
Domenico Palombo (Italy),
Igor Koncar (Serbia)**

16:00-16:50 **Part A**

16:00-16:20 Antithrombotic treatment in peripheral arterial disease
Stavros Spiliopoulos (Greece)

16:21-16:40 Antithrombotic treatment in carotid artery disease
Andreas Lazaris (Greece)

16:41-16:50 *Discussion*

16:51-17:40 **Part B**

16:51-17:10 NOACs in the treatment of VTE. Clinical implications
Miltiadis Matsagkas (Greece)

17:11-17:30 What is new in the recently published ESC guidelines for pulmonary embolism?
Spyros Vasdekis (Greece)

17:31-17:40 *Discussion*

17:40-17:50 **Coffee break**

17:51-19:00 **Part C**

17:51-18:45 Managing patients under anti-thrombotic therapy to undergo interventional procedures
Eleni Arnaoutoglou (Greece)

18:46-19:00 *Discussion*

Parallel Session

09:00-15:30 Modern Therapeutic Interventions in Venous Diseases

Case discussion and venous ultrasound

Jointly organized with the European Society for Vascular Surgery (ESVS)

Convenor: **Cees Wittens (The Netherlands)**

MINOS I HALL

09:00-12:00 Part I: Workshop: Varicose Veins and DVT - diagnostics and treatment

Station 1: Ultrasound on chronic venous insufficiency

Dimitrios Kardoulas (Greece)

Station 2: Compression for limb oedema

**Maria-Christina Papadopoulou (Greece),
Roumiana Salta-Stankova (Greece),
Georgia Ambatziadou (Greece)**

Station 3: Foam Sclerotherapy and Ultrasound guided Vein Access

Dimitrios Kontothanassis (Italy)

Station 4: Endovenous procedures with laser (Biolitec)

**Athanasios Giannoukas (Greece),
Christos Karathanos (Greece)**

Station 5: Endovenous procedures with RF (VNUS)

Andreas Lazaris (Greece)

Station 6: Tumescant less Endovenous procedures (ClarviVein)

Steve Elias (USA)

Station 7: Steam Therapy for varicose veins

Prodromos Papapavlou (Greece)

12:00-12:30 Break

12:30-15:30 **Part II: Workshop: Varicose Veins and DVT - diagnostics and treatment**

Station 1: Ultrasound DVT diagnostics
Nicos Labropoulos (USA)

Station 2: Ambulatory Venous Compression
- venous ulcher
**Maria-Christina Papadopoulou (Greece),
Roumiana Salta-Stankova (Greece),
Georgia Ambatziadou (Greece)**

Station 3: DVT treatment with AngioJet
Antonios Gasparis (USA)

Station 4: Deep venous stenting
Cees Wittens (The Netherlands)

Station 5: IVUS
Mark Meissner (USA)

Station 6: IVC filters
Apostolos Tassiopoulos (USA)

Station 7: Laser treatment for varicose veins
(Angiodynamics)
**Athanasios Giannoukas (Greece),
Nicos Rousas (Greece)**

14:30-16:30 ORAL PRESENTATIONS SESSION

Chairmen: **Nicos Labropoulos (USA),
Christos Ioannou (Greece),
Gabriel Szendro (Israel)**

Award Committee:
**Gabriel Szendro (Israel),
Lazar Davidovic (Serbia),
Antonios Gasparis (USA)**

Review Committee:
**Martin Veller (South Africa),
Gabriel Szendro (Israel),
Johannes Lammer (Austria)**

Parallel Session - **MINOS I HALL**

14:30-16:30 e-POSTER PRESENTATIONS SESSION

Chairmen-Award Committee:
**Apostolos Tassiopoulos (USA),
Steve Elias (USA),
Mark Meissner (USA),
Pavlos Antoniadis (Greece)**

Review Committee:
**Martin Veller (South Africa),
Gabriel Szendro (Israel),
Johannes Lammer (Austria)**

PASIPHAE HALL

**16:30-17:30 SCIENTIFIC SESSION I
Chronic Venous Disease I**

*Jointly organized with the
Orient Society for Vascular Surgery*

Moderators:
**Louay Altarazi (Syria),
Emmanouil Touloupakis (Greece),
Theodoros Kostas (Greece)**

16:30-16:39 Transcutaneous Nd:Yag Laser for the treatment of telangiectasia and spider veins
Elias Obeid (Lebanon)

16:40-16:49 A New Look for Venous Ultrasound Anatomy in Varicose Veins: Review of more than 1000 patients
Wassila Taha (Egypt)

- 16:50-16:59 Iliac vein stenting in the context of ilio-femoral DVT
Rashad Bishara (Egypt)
- 17:00-17:09 Small saphenous vein approach
Tarek Ghandour (Lebanon)
- 17:10-17:19 Pelvic Congestion Syndrom approach, special tips and tricks
Louay Altarazi (Syria)
- 17:20-17:30 *Discussion*

PASIPHAE HALL

17:30-18:45 SCIENTIFIC SESSION II
Chronic Venous Disease II

Moderators:

Nicos Labropoulos (USA),
Konstantinos Katsenis (Greece),
Prodromos Papapavlou (Greece)

- 17:30-17:39 Controversial issues on vein disease
Mark Meissner (USA)
- 17:40-17:49 Residual, recurrent and new varicosities
Dimitrios Kontothanasis (Italy)
- 17:50-17:59 Many saphenous veins are treated unnecessarily
Nicos Labropoulos (USA)
- 18:00-18:09 Does the ablation method alter the clinical outcome?
Steve Elias (USA)
- 18:10-18:19 The controversy of the perforator veins
Cees Wittens (The Netherlands)
- 18:20-18:29 Which patients with pelvic varices benefit from the treatment?
Antonios Gasparis (USA)
- 18:30-18:45 *Discussion*
- 18:45-19:00 Break - Visit of the exhibition area**

19:00-20:15 SCIENTIFIC SESSION III
Venous Thromboembolism

Moderators:

**Cees Wittens (The Netherlands),
 Spyros Vasdekis (Greece),
 Ahmet Tulga Ulus (Turkey)**

- 19:00-19:09 Management of calf DVT - make it simple
Nicos Labropoulos (USA)
- 19:10-19:19 What is the progress on prevention of post-thrombotic syndrome?
Mark Meissner (USA)
- 19:20-19:29 The current burden of the IVC filters
Apostolos Tassiopoulos (USA)
- 19:30-19:39 Critical evaluation of the new oral anticoagulants
Ioannis Kakisis (Greece)
- 19:40-19:49 Updates on the treatment of massive and sub-massive pulmonary embolism
Luis Leon (USA)
- 19:50-19:59 How the modern phlebologist should be trained?
Steve Elias (USA)
- 20:00-20:15 *Discussion*

PASIPHAE HALL

20:15-21:15 OPENING CEREMONY

Welcome Message from LIVE 2015 Directors

Greetings-Official Opening

Best Oral & e-Poster Presentation Award

Prof. A. Katsamouris: The friend, the physician and the Academic man (film presentation)

PROF. ASTERIOS KATSAMOURIS LECTURE
Rationale and benefits from vascular surgical training with life-like pulsatile flow models

Invited speaker:

Hans-Henning Eckstein (Germany)

21:15 Welcome Reception

09:00-10:00 SCIENTIFIC SESSION IV
Peripheral Arterial Disease - Diabetic Foot

Moderators: **Dimitrios Tsetis (Greece),**
Christos Klonaris (Greece),
Marios Moustardas (Greece)

- 09:00-09:09 Diabetic foot: Advanced BTK interventions
Dimitrios Tsetis (Greece)
- 09:10-09:19 POBA, DEB, BMS or DES for the SFA
 revascularization
Stefan Muller-Hulsbeck (Germany)
- 09:20-09:29 Bioabsorbable vascular scaffolds in PAD:
 where are we now?
Johannes Lammer (Austria)
- 09:30-09:39 Fem-distal bypass with saphenous vein is
 still an unsurpassed choice of treatment for
 diabetic patients
Martin Veller (South Africa)
- 09:40-09:49 Diabetic Vascular Disease: new reporting
 standards are required
Philip Chan (UK)
- 09:50-10:00 *Discussion*

10:00-11:00 SCIENTIFIC SESSION V
**Hellenic-German Forum on the current
 and future patterns of Arterial Disease
 Management**

*Jointly organized with the
 German Society for Vascular Surgery*

Moderators:

**Tilo Koelbel (Germany),
 Christos Liapis (Greece),
 Odysseas Zoras (Greece)**

- 10:00-10:09 Current status and future developments in endovascular treatment of chronic aortic dissections
Tilo Koelbel (Germany)
- 10:10-10:19 Surgeon-modified and off-the-shelf devices to treat acute complex aortic aneurysms
Nikolaos Tsilimparis (Germany)
- 10:20-10:29 Fenestrated and branched endografting of pararenal and thoraco-abdominal aortic aneurysms
George Vourliotakis (Greece)
- 10:30-10:39 Novel indications and use of parallel grafts expand the applicability of the chimney technique
**Konstantinos Donas (Germany),
 Georgios Pitoulis (Greece)**
- 10:40-11:00 *Discussion*
- 11:00-11:25 Break - Visit of the exhibition area**

PASIPHAE HALL

11:25-11:40 INVITED LECTURE I
**Interventional access maintenance:
 how far can we go?**

Chairmen: **Ioannis Tsolakis (Greece),
 Miltos Lazarides (Greece),
 Nikolaos Bessias (Greece)**

Invited Speaker:

Dimitrios Karnabatidis (Greece)

11:40-12:05 DEBATE

**Elderly end-stage renal disease patients:
autologous access at all cost or liberal
use of grafts and catheters?**

Moderators: **Ioannis Tsolakis (Greece),
Miltos Lazarides (Greece),
Nikolaos Bessias (Greece)**

11.40-11.42 The audience is voting

11.43-11.52 Autologous access at all costs
Selcuk Baktiroglu (Turkey)

11.53-12.02 Liberal use of grafts and catheters
David Shemesh (Israel)

12.03-12.05 The audience is voting

12:05-13:05 SATELLITE SESSION

13:05-14:00 SCIENTIFIC SESSION VI

Hot topics in Vascular Anaesthesia

Moderators: **Eleni Arnaoutoglou (Greece),
Petros Hatzigakis (Greece),
Georgios Halkiadakis (Greece)**

13.05-13.14 Preoperative assessment, intra- and peri-
operative care: What is the evidence that
dedicated Vascular Anesthetists can improve
outcomes?
Meryl Davis (UK)

13.15-13.24 Improving communication and teamwork
in the perioperative setting
Aikaterini Chatzimichali (Greece)

13.25-13.34 Monitored Anesthesia Care for EVAR for
AAA. Less is more
Eleni Arnaoutoglou (Greece)

13.35-13.44 Recent guidelines on Perioperative
Cardiovascular Evaluation and Management
of Patients Undergoing Noncardiac Surgery
Theodosia Vogiatzaki (Greece)

13.45-14.00 *Discussion*

14:00-14:15 Break - Visit of the exhibition area
Lunch boxes available at the exhibition area

PASIPHAE HALL

14:15-15:15 SATELLITE LUNCH SESSION

PASIPHAE HALL

15:15-15:30 INVITED LECTURE II
**New devices and techniques in CAS:
Clinically meaningful?**

Chairmen: **Elias Brountzos (Greece),
Dimitrios Maras (Greece),
George Sfyroeras (Greece)**

Invited Speaker: **Sumaira Macdonald (USA)**

PASIPHAE HALL

15:30-16:00 SATELLITE SESSION

PASIPHAE HALL

16:00-16:45 MEET THE EXPERTS SESSION I
How I do it?

Moderators:
**Alexandros Gougoulakis (Greece),
Martin Veller (South Africa),
Kyriakos Ktenidis (Greece)**

16:00-16:09 Endovascular management of complex aortoiliac occlusion: technique to avoid surgery
Samer Koussayer (Saudi Arabia)

16:10-16:15 *Discussion*

16:16-16:25 Open repair of AAA in the presence of the horseshoe kidney
Lazar Davidovic (Serbia)

16:26-16:30 *Discussion*

16:31-16:40 Endovascular repair of pararenal AAA with Chimney technique
Mario Lachat (Switzerland)

16:41-16:45 *Discussion*

Friday, May 22nd, 2015

LIVE2015 MAIN PROGRAMME

08:15-15:00 VASCULAR NURSING SESSION

The session applies only to Greek participants

For more information please collect the program from LIVE 2015 secretariat.

PASIPHAE HALL

09:00-10:20 SCIENTIFIC SESSION VII

All about thoracic and abdominal aorta

Jointly organized with the European Society for Cardiovascular & Endovascular Surgery (ESCVS)

Moderators:

**Miltiadis Matsagkas (Greece),
Michael Jacobs (The Netherlands),
Vasileios Tzilalis (Greece)**

- 09:00-09:09 An update in the Endovascular management of chronic post-dissection aneurysms
Athanasios Katsargyris (Germany)
- 09:10-09:19 Aortic penetrating atherosclerotic ulcers: Aetiology, diagnosis and management in the endovascular era
Domenico Palombo (Italy)
- 09:20-09:29 EVAR versus OSR in rAAA: what do we know so far?
Johannes Lammer (Austria)
- 09:30-09:39 Surveillance intervals in Small AAA
Janet Powell (UK)
- 09:40-09:49 AAA: The role of open surgery in the endovascular era
Franco Grego (Italy)
- 09:50-09:59 Indications for treatment of AAA in women
Janet Powell (UK)
- 10:00-10:20 *Discussion*
- 10:20-10:40 Break - Visit of the exhibition area**

10:40-11:40 SCIENTIFIC SESSION VIII**Complications in Vascular Interventions***Jointly organized with the
World Federation of Vascular Surgery*Moderators:**Sebastian DeBus (Germany),
John Wolfe (UK),
Chrysostomos Maltezos (Greece)**

- 10:40-10:50 Complications of carotid stenting
Elias Brountzos (Greece)
- 10:51-11:00 Transcatheter embolization of iatrogenic
vascular injuries
Miltiadis Krokidis (UK)
- 11:01-11:10 Strategies in the management of aorto-
enteric fistula
John Wolfe (UK)
- 11:11-11:20 Prolonged use of temporary shunts for limb
salvage in critically injured trauma patients
Gabriel Szendro (Israel)
- 11:21-11:40 *Discussion*

PASIPHAE HALL

11:40-11:55 KEYNOTE LECTURE**Staged open and endovascular repair of
TAAA to reduce the risk of paraplegia**Chairmen: **Mario Lachat (Switzerland),
Natzi Sakalihasan (Belgium),
Miltos Lazarides (Greece)**Invited Speaker:**Michael Jacobs (The Netherlands)**

- 11:55-12:05 Break - Visit of the exhibition area**

PASIPHAE HALL

12:05-12:50 SATELLITE SESSION

12:50-14:10 SCIENTIFIC SESSION IX
Update in carotid disease management

Moderators:

**Hans-Henning Eckstein (Germany),
 Achilles Chatziioannou (Greece),
 Dimitrios Christopoulos (Greece)**

12:50-13:00 Why the SPACE-2 trial failed to recruit more than 500 patients
Hans-Henning Eckstein (Germany)

13:01-13:10 Intervention may not be needed to all patients with severe asymptomatic stenosis: The rationale for a new natural history assessing the role of Optimum Medical Treatment
Stavros Kakkos (Greece)

13:11-13:20 Aortic arch markers for selecting patients for carotid intervention
Achilleas Chatziioannou (Greece)

13:21-13:30 How to adapt different CAS strategies for different carotid morphologies?
Sumaira Macdonald (USA)

13:31-13:40 How to select the appropriate stent for a safe CAS?
Konstantinos Papazoglou (Greece)

13:41-13:50 Great evidence - 5000 patients in the ACST trials
Richard Bulbulia (UK)

13:51-14:10 Discussion
Christos Liapis (Greece)

14:10-14:20 Break - Visit of the exhibition area
Lunch boxes available at the exhibition area

14:20-15:05 SATELLITE LUNCH SESSION

15:05-16:45 MEET THE EXPERTS SESSION II
Difficult case scenarios

Moderators: **Lazar Davidovic (Serbia),
 Apostolos Karantanas (Greece),
 Konstantinos Filis (Greece)**

- 15:05-15:13 Case 1: Unusual treatment of EVAR complications - Presentation of four cases
**Ioannis Tsolakis (Greece),
 Dimitrios Karavias (Greece)**
- 15:14-15:21 *Discussion*
- 15:22-15:30 Case 2: NICE operation resulting thigh amputation. Is it a cause for celebration?
Alexandros Gougoulakis (Greece)
- 15:31-15:38 *Discussion*
- 15:39-15:47 Case 3: The use of covered stents in the treatment of distal internal carotid artery pathologies
**Athanasios Giannoukas (Greece),
 Stylianos Koutsias (Greece),
 Konstantinos Spanos (Greece)**
- 15:48-15:56 *Discussion*
- 15:57-16:04 Case 4: Standard endovascular repair of a huge aorto-iliac aneurysm with very severe neck angulation
**Miltiadis Matsagkas (Greece),
 George Kouvelos (Greece)**
- 16:05-16:13 *Discussion*
- 16:14-16:21 Case 5: Unexpected iliac limb collapse during EVAR
**Efstratios Georgakarakos (Greece),
 Nikolaos Schoretsanitis (Greece)**
- 16:22-16:30 *Discussion*

16:31-16:38 Case 6: Primary Aortocaval Fistula -
Diversity of Clinical Presentation
**Stella Lioudaki (Greece),
Dimitrios Pantidis (Greece),
Alexandros Kafetzakis (Greece),
Christos Ioannou (Greece)**

16:39-16:45 *Discussion*

Panel of Expert Discussants:

**S. Debus (Germany), M. Veller (South Africa),
J. Lammer (Austria), M. Jacobs (The Netherlands),
H.-H. Eckstein (Germany), J. Wolfe (UK),
M. Lachat (Switzerland), G. Szendro (Israel),
S. Muller-Hulsbeck (Germany), C. Liapis (Greece),
D. Tsetis (Greece), C. Klonaris (Greece),
K. Papazoglou (Greece)**

PASIPHAE HALL

16:45-17:30 LECTURES ON INNOVATIVE CONCEPTS

Chairmen: **Johannes Lammer (Austria),
Janet Powell (UK),
Christos Klonaris (Greece)**

16:45-16:55 **Lecture 1**
Vascular Mimetic Implants in the Femoro-
popliteal Arterial segment: A novel and
proven superior concept
Luis Leon (USA)

16:56-17:00 *Discussion*

17:01-17:10 **Lecture 2**
PET/CT in the abdominal aneurysm:
correlation with the cellular and molecular
alterations in the aneurysmal wall
Natzi Sakalihan (Belgium)

17:11-17:15 *Discussion*

17:16-17:25 **Lecture 3**
Carotid stenting with Roadsaver stent
Stefan Muller-Hulsbeck (Germany)

17:26-17:30 *Discussion*

17:30-18:00 SATELLITE LECTURE

18:00-18:20 INVITED LECTURE III
**The FastVASCular concept:
a multidisciplinary approach for early
recovery after Aortic Operations**

Chairmen:

**Domenico Palombo (Italy),
Franco Grego (Italy),
Stefan Muller-Hulsbeck (Germany)**

Invited Speaker:

Sebastian Debus (Germany)

18:20

CLOSING CEREMONY

Draw

Closing Remarks

A

Altarazi Louay

Founder, Orient Society for Vascular Surgery, Director, Orient Endovascular Symposium "OES", Head, Syrian Endovascular Chapter & Arab Endovascular Group, Syria

Ambatziadou Georgia

Nurse, University Hospital of Larissa, Larissa, Greece

Antoniadis Pavlos

Consultant Vascular Surgeon, Department of Vascular Surgery, Konstantinopouleio General Hospital of Nea Ionia «Agia Olga», Athens, Greece

Arnaoutoglou Eleni

Associate Professor of Anaesthesiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

B

Baktiroglu Selcuk

Professor of Surgery, Faculty of Medicine, University of Istanbul, Istanbul, Turkey

Bessias Nikolaos

Vascular Surgeon, Director, Department of Vascular Surgery, Red Cross General Hospital of Athens, Athens, Greece

Bishara Rashad

Vascular Surgeon, Department of Vascular Surgery, ElSahel Teaching Hospital, Shoubra, Cairo, Egypt

Brountzos Elias

Professor of Interventional Radiology, Faculty of Medicine, School of Health Sciences, University of Athen, Athens, Greece

Bulbulia Richard

Consultant Vascular Surgeon, Clinical Trial Service Unit, University of Oxford, Oxford, UK

C

Chan Philip

Reader in Vascular Surgery, Academic Vascular Unit, Northern General Hospital, Sheffield, UK

Chatziioannou Achilleas

Professor of Interventional Radiology, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Chatzimichali Aikaterini

Consultant Anaesthesiologist, Department of Anaesthesiology, University Hospital of Heraklion, Crete, Greece

Christopoulos Dimitrios

Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

D

Davidovic Lazar

Professor of Vascular Surgery, School of Medicine, Faculty of Medical Sciences, University of Belgrade, Chief, Clinic for Vascular and Endovascular Surgery, Clinical Centre of Serbia, Belgrade, Serbia

Davis Meryl

Consultant Vascular Surgeon, Royal Free Hospital and the North Middlesex University Hospital NHS Trust, Royal Free Hospital, London, UK

Debus Sebastian

Professor of Vascular Surgery, Chairman, Department of Vascular Medicine, Vascular Surgery - Endovascular Interventions - Angiology, German Aortic Center Hamburg, University Heart Center Hamburg - Eppendorf, Hamburg, Germany

Donas Konstantinos

Assistant Professor of Vascular Surgery, Munster University, Clinic for Vascular and Endovascular Surgery, Munster University Hospital & St. Franziskus Hospital, Munster, Germany

E

Eckstein Hans-Henning

Professor of Vascular Surgery, Department of Vascular and Endovascular Surgery/Vascular Center, Klinikum rechts der Isar Hospital, Technischen Universität München, Munich, Germany

Elias Steve

Director, Center for Vein Disease, Director, Wound Care Center, Englewood Hospital and Medical Center, Englewood, New Jersey, USA

F

Filis Konstantinos

Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

G

Gasparis Antonios

Professor of Surgery, Division of Vascular Surgery, Assistant Chief Medical Officer, Director, Stony Brook Vein Center, Stony Brook University Medical Center, New York, USA

Georgakarakos Efstratios

Assistant Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, Alexandroupolis, Greece

Ghandour Tarek

Giannoukas Athanasios

Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Gougoulakis Alexandros

Vascular Surgeon, Athens, Greece

Grego Franco

Professor of Vascular Surgery, Department of Cardiac, Thoracic and Vascular Sciences, Faculty of Medicine and Surgery, University of Padua, Padua, Italy

H

Halkiadakis Georgios

Professor of Surgery, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

Hatzigakis Petros

Consultant Vascular Surgeon, Department of Vascular Surgery, General Hospital of Athens "G.Gennimatas", Athens, Greece

Ioannou Christos

Assistant Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

J

Jacobs Michael

Professor of Surgery, Chairman, Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands

K

Kafetzakis Alexandros

Consultant Vascular Surgeon, Vascular Surgery Unit, Department of Cardiothoracic and Vascular Surgery, University General Hospital of Heraklion, Heraklion, Crete, Greece

Kakisis Ioannis

Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Kakkos Stavros

Assistant Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece

Karantanas Apostolos

Professor of Radiology, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

Karathanos Christos

Vascular Surgeon, Department of Vascular Surgery, University General Hospital of Larissa, Larissa, Greece

Karavias Dimitrios

Resident in Vascular Surgery, Department of General Surgery, University Hospital of Patras, Rion, Patras, Greece

Kardoulas Dimitrios

Biomedical Engineer, Department of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

Karnabatidis Dimitrios

Associate Professor of Radiology, Department of Radiology, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece

Katsargyris Athanasios

Resident in Vascular Surgery, Department of Vascular & Endovascular Surgery, Paracelsus Medical University, Nuremberg, Germany

Katsenis Konstantinos

Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Klonaris Christos

Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Koelbel Tilo

Professor of Surgery, University of Hamburg, Consultant Vascular Surgery, University Heart Center Hamburg, Hamburg, Germany

Koncar Igor

Vascular Surgeon, Clinic for Vascular and Endovascular Surgery, Serbian Clinical Center, Belgrade, Serbia

Kontothanassis Dimitrios

Professor of Vascular Surgery, General Director, Mediclinic Hospital, Ferrara, Italy

Kostas Theodoros

Vascular Surgeon, Department of Vascular Surgery, University General Hospital of Heraklion, Heraklion, Crete, Greece

Koussayer Samer

Koutsias Stylianos

Lecturer in Vascular-Endovascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Kouvelos George

Vascular Surgeon, Vascular Surgery Unit, University of Ioannina, Ioannina, Greece

Krokidis Miltiadis

Consultant Vascular and Interventional Radiologist, Cambridge University Hospitals NHS Foundation Trust, Department of Radiology, Addenbrooke's Hospital, Cambridge, UK

Ktenidis Kyriakos

Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

L

Labropoulos Nicos

Professor of Surgery and Radiology, Director, Vascular Laboratory, Department of Surgery, Stony Brook University Medical Center, New York, USA

Lachat Mario

Professor of Vascular Surgery, Head of Vascular Surgery, University Hospital Zurich, Zurich, Switzerland

Lammer Johannes

Professor of Radiology, Director of Cardiovascular and Interventional Radiology, Vicechairman, Department of Biomedical Imaging and Image-guided, Therapy Medical University Vienna, Vienna, Austria

Lazarides Miltos

Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, Alexandroupolis, Greece

Lazaris Andreas

Assistant Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Leon Luis

Assistant Professor of Surgery, Department of Vascular and Endovascular Surgery, Tucson Medical Center, Tucson, Arizona, USA

Liapis Christos

Professor Emeritus of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Lioudaki Stella

Consultant Vascular Surgeon, Vascular Surgery Unit, Department of Cardiothoracic and Vascular Surgery, University General Hospital of Heraklion, Heraklion, Crete, Greece

M

Macdonald Sumaira

Maltezos Chrysostomos

Consultant Vascular Surgeon, Director, Department of Vascular Surgery, KAT General Hospital of Athens, Athens, Greece

Maras Dimitrios

Vascular Surgeon, Department of Vascular Surgery, Red Cross General Hospital of Athens, Athens, Greece

Matsagkas Miltiadis

Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

Meissner Mark

Professor of Vascular Surgery, Department of Surgery, University of Washington, Seattle, Washington, USA

Moustardas Marios

Vascular Surgeon, F. Director, Department of Thoracic-Vascular Surgery, General Hospital of Chania, Chania, Greece

Muller-Hulsbeck Stefan

Professor of Radiology, Head, Department of Diagnostic and Interventional Radiology/Neuroradiology, Diako Flensburg, Academic Hospitals Flensburg, Flensburg, Germany



Obeid Elias

Oto Oztekin

Professor of Thoracic and Cardiovascular Surgery, Founder Chairman, Department of Thoracic and Cardiovascular Surgery, Faculty of Medicine, Dokuz Eylul University of Izmir, President, ESCVES, Izmir, Turkey



Palombo Domenico

Professor of Vascular Surgery, School of Medicine, University of Genoa, Genoa, Italy, President of the European Society for Cardiovascular and Endovascular Surgery (ESCVS)

Pantidis Dimitrios

Resident in Vascular Surgery, Head of Vascular Surgery Unit, Department of Cardiothoracic and Vascular Surgery, University General Hospital of Heraklion, Heraklion, Crete, Greece

Papadopoulou Maria-Christina

Physiotherapist, Lymphoedema Center, Department of Vascular Surgery, University General Hospital of Larissa, Larissa, Greece

Papapavlou Prodromos

Vascular Surgeon, Director, Department of Vascular Surgery, Metropolitan Hospital of Athens, Athens, Greece

Papazoglou Konstantinos

Associate Professor of Surgery-Vascular Surgery, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Pitoulas Georgios

Assistant Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Powell Janet

Visiting Professor of Vascular Surgery, Department of Surgery & Cancer, Faculty of Medicine, Charing Cross Hospital, Imperial College London, London, UK

R

Rousas Nicos

Vascular Surgeon, Department of Vascular Surgery, University General Hospital of Larissa, Larissa, Greece

S

Sakalihan Natzi

Professor of Cardiovascular Surgery, School of Medicine, Sart-Tilman University, Liege, Belgium

Salta-Stankova Roumiana

Physiotherapist, Lymphoedema Center, Department of Vascular Surgery, University General Hospital of Larissa, Larissa, Greece

Schoretsantis Nikolaos

Resident in Vascular Surgery, Department of Vascular Surgery, University General Hospital of Evros, Alexandroupolis, Greece

Sfyroeras George

Vascular Surgeon, Department of Vascular Surgery, Attikon University General Hospital of Athens, Athens, Greece

Shemesh David

Vascular Surgeon, Director of Vascular Access Unit, Director of Noninvasive Vascular Institute, Shaare Zedek Medical Center, Jerusalem, Israel

Spanos Konstantinos

Resident in Vascular Surgery, Department of Vascular Surgery, University General Hospital of Larissa, Larissa, Greece

Szendro Gabriel

Professor of Vascular Surgery, Head, Vascular Surgery Department, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel

T

Taha Wassila

Vascular Surgeon, Department of Vascular Surgery, ElSahel Teaching Hospital, Shoubra, Cairo, Egypt

Tassiopoulos Apostolos

Professor and Chief, Division of Vascular Surgery, Program Director, Vascular Surgery Residency & Fellowship, Stony Brook University Medical Center, New York, USA

Touloupakis Emmanouil

Consultant Vascular Surgeon, Heraklion, Crete, Greece

Tsetis Dimitrios

Associate Professor of Interventional Radiology, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

Tsilimparis Nikolaos

Resident in Vascular Surgery, Department of Vascular Medicine Vascular Surgery - Endovascular Interventions - Angiology, German Aortic Center Hamburg, University Heart Center Hamburg - Eppendorf, Hamburg, Germany

Tsolakis Ioannis

Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece

Tzilalis Vasileios

Vascular - Endovascular Surgeon, Head, Department of Vascular Surgery, 401 General Army Hospital of Athens, Athens, Greece

U

Ulus Ahmet Tugla

V

Vasdekis Spyros

Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Veller Martin

Professor of Vascular Surgery, Head, Department of Surgery, University of Witwatersrand, Johannesburg, South Africa

Vogiatzaki Theodosia

Associate Professor of Anaesthesiology, Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, Alexandroupolis, Greece

Vourliotakis George

Vascular Surgeon, Deputy Director, Division of Vascular Surgery, Department of Surgery, 401 General Military Hospital of Athens, Athens, Greece

W

Wittens Cees

Professor of Venous Surgery, Head, Department of Venous Surgery, Maastricht University Medical Center, Maastricht, The Netherlands

Wolfe John

Consultant Vascular Surgeon, Department of Vascular Surgery, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK

Z

Zoras Odysseas

Professor of Surgery, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

Powerful patency. A decade of performance.



Overall weighted average primary patency

**More Data.
More Patients.
More
Confidence.***

- 100,000+ devices implanted
- 30+ clinical publications
- 93% 9-year limb salvage²
- 1629 limbs studied
- 1 RCT demonstrating superior primary patency compared to standard ePTFE³
- 33% reduction in 3-year cumulative cost compared to standard ePTFE⁴
- 50% reduction in the risk of graft occlusion compared to standard ePTFE in CLI patients³



**Walk through the data –
Explore the interactive data summary at
goremedical.com/propatenperformance**



**PERFORMANCE
through data**

* As compared to clinical studies listed on clinicaltrials.gov for peripheral arterial bypass.

1. Overall weighted average primary patency is based on data from 11 peer-reviewed publications meeting pre-determined inclusion criteria. Visit goremedical.com/propatenperformance to see inclusion criteria, explore the data, see publications, and request reprints.
2. Monaca V, Battaglia G, Turiano SA, Tringale R, Catalfamo S. Sub popliteal revascularization. Criteria analysis for use of E-PT.F.E. (Propaten®) as first choice conduit. *Italian Journal of Vascular & Endovascular Surgery*. In press.
3. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian Propaten® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomised clinical controlled multi-centre trial. *European Journal of Vascular & Endovascular Surgery* 2011;41(5):668-673.
4. Value in Performance. W. L. Gore & Associates, Inc. Web site. www.goremedical.com/resources/dam/assets/AQ0599-EN2.pdf. Published September 2012. Accessed September 30, 2013.

W. L. Gore & Associates, Inc. • Flagstaff, AZ 86004 • goremedical.com


Products listed may not be available in all markets.

GORE®, PERFORMANCE THROUGH DATA, PROPATEN®, and designs are trademarks of W. L. Gore & Associates.

© 2015 W. L. Gore & Associates, Inc. AU3124-EU1 FEBRUARY 2015

Trusted Performance

TODAY and TOMORROW



Proven Now and Positioned for the Future

More than 15 years of worldwide **EXPERIENCE** and 190,000 devices distributed.

Proven **DURABILITY** backed by extensive clinical and commercial data**.

More opportunities to optimize infrarenal seal with intuitive **REPOSITIONABLE** delivery system.

Learn more at goremedical.com/excluder



AAA ENDOPROSTHESIS

PERFORMANCE
by design

*Products are under development and not available or approved for sale in any market. **Data on file.

W. L. Gore & Associates, Inc. • Flagstaff, AZ 86004 • goremedical.com

Products listed may not be available in all markets.

GORE®, EXCLUDER®, PERFORMANCE BY DESIGN, and designs are trademarks of W. L. Gore & Associates. © 2015 W. L. Gore & Associates, Inc. AU3125-EU1 FEBRUARY 2015

General Information

Venue

Aquila Atlantis Hotel

2 Ygias Str, Heraklion, Crete, 71202, Greece

Tel: +30 2810 229 103

Fax: +30 2810 226 265

Email: reservations.at@aquilahotels.com

Web: www.theatlantishotel.gr

Dates & Hours

Registration

Wednesday, May 20, 2015 14.30 - 19.00

Thursday, May 21, 2015 08.30 - 20.15

Scientific Programme

Thursday, May 21, 2015 09.00 - 21.15

Friday, May 22, 2015 09.00 - 16.45

Saturday, May 23, 2015 08.15 - 18.20

Secretariat/Technical Support/Exhibition

Thursday, May 21, 2015 08.30 - 21.15

Friday, May 22, 2015 08.30 - 16.45

Saturday, May 23, 2015 08.00 - 18.20

Opening Ceremony

Thursday, May 21, 2015 20.15 - 21.15

Welcome Reception

Thursday, May 21, 2015 21.15

Closing Ceremony

Saturday, May 23, 2015 18.20

Official Language

The official language of LIVE 2015 is **English**.

Simultaneous translation (interpretation) is not provided.



Official Website


Find LIVE 2015 at **www.live2015.gr**.

Contact: **info@live2015.gr** & **admin@live2015.gr**

Newsletter: If you wish to receive information and news about future LIVE symposiums or/and relative vascular courses/congresses, you may subscribe in the Keep me Updated Subscription Form available on the website.

Webcasting

According to the LIVE 2015 Directors' willingness, this year's Congress (main hall) will be recorded and broadcasted (in a second time) via the **Institute of Vascular Disease's** portal, <http://www.ivd.gr>.

Kindly sponsored by  **Medtronic**

Halls

LEVEL 1 (Ground Floor)

Main Hall: **PASIPHAE**

- Main Programme
- Oral Presentations

Parallel Sessions Hall: **APOLLO**

- Summer School of the ESCVS
- Simulator training on Bolton's Medical stent graft systems - Treovance (AAA) & Relay (TAA).

INDUSTRY EXHIBITION

LEVEL -1

Parallel Sessions Hall: **MINOS I**

- Pre Symposium Course (Part I)
- e-Poster Presentations

Parallel Sessions Hall: **MINOS II**

- Pre Symposium Course (Part II)
- Vascular Nursing Session

INDUSTRY EXHIBITION

MAJOR SPONSORS



Exhibition & Draw

LIVE 2015 is accompanied by a major exhibition where pharmaceutical and/or equipment/device industries will display relevant products and therapeutic developments. The exhibition forms an integral component of the symposium giving the exhibitors the opportunity to promote their activities, research and technologies.

Visit the exhibition and take part in the prize Draw!

We invite you all to catch a glimpse of the industries' latest developments. Visit the exhibition stands, collect **one stamp from each stand** (on the special card which you will find in your bag) and get a chance to be the winner of the special LIVE 2015 prize draw, that will take place during the Closing Ceremony on Saturday, May 23, 2015. Be all there!

Be the winner of a(n):

- ✓ iPad
- ✓ Mobile hard disk drive (1TB)
- ✓ Free registration and accommodation for LIVE 2016 symposium to be held on May 19-21, 2016 in Ioannina, Greece

Internet Corners

At the exhibition area, there will be "Internet Corner(s)", where registered participants will be able to use the available **laptops** for their work and for free access to internet.

On the desktops participants will also find the:

- **LIVE 2015 E-Abstract Book (PDF)**
(Oral & E-Poster Presentations abstracts)
- **E-Final Programme (PDF)**
- PPT templates
- other files with useful information

Name Badge – Scanning (*mandatory*)

All Participants upon confirmation of their registration at the Secretariat will be provided with a **unique Name Badge**, which must be **scanned**, in order to record CME Credits for their attendance.

General Information

Your personal name badge is your passport to all scientific sessions and the exhibition area. All participants are required to wear their badges (visibly) during all sessions. Make sure you will not forget to take always with you this unique name badge.

It must be clearly understood that barcode badges must be scanned **before entering AND after exiting** the session Halls (in order the exact duration of attendance to be recorded).

Remember



Scan your badge to record your attendance!

No scanned badges - No credits!

Notes:

- Name badge already used for recording credits of attendance cannot be replaced with a second badge (as credits will not be allocated properly).
- Name badges are also necessary to be returned to the Secretariat for receiving the Certificate(s) of Attendance.
- Time slots for satellite sessions and breaks cannot be recorded

Also note:

According to the Regulation of the **Greek National Organization of Medicines**, participation **for at least of 60%** of the total duration of the scientific programme must be secured and recorded!

Certificate of Attendance

All registered participants are entitled to receive a **Certificate of Attendance**. The Certificate will be issued only upon return of the name badge and the Evaluation Form (completed) at the Secretariat desk onsite by the end of the Congress.

Participants, who will register for and participate in the Pre-Symposium Courses or/and the Vascular Nursing Session will also be entitled to receive the **Relative Certificates** (after completion).

MAJOR SPONSORS



Bayer



Medtronic

General Information

Evaluation Form (*mandatory*)

All participants by the end of the Symposium will be requested to complete and deliver to the Secretariat a relative Evaluation Form (anonymous) as feedback of their experience during the symposium. Official Feedback Report (based on participants' opinion) is required by the EACCME (European Accreditation Council for Continuing Medical Education-UEMS) in the framework of the symposium's accreditation (with CME Credits).

Technical Support Personnel

The technical support personnel will be operating during the sessions of the scientific programme outside the session Halls in order to assist speakers/presenting authors with their Presentations.

Liability and Insurance

The Organizers as well as the Organizing-Administrative Bureau of LIVE 2015 will assume no liability for injuries or losses of any nature incurred by participants and/or accompanying persons, or for the damage, loss or theft of their personal property during the Symposium. Participants are advised to take out their own health, travel and personal insurances.

Mobile Phones

Everyone is requested to switch off his/her mobile phone while in session Halls.

Organizing-Administrative Bureau/Secretariat



Conferre Ltd: *"The Art of Bringing People Together"*
St. Niarhou Avenue, GR 451 10 Ioannina, Greece
Tel: +30 26510 68610, Fax: +30 26510 68611
E-mail: info@conferre.gr, Website: www.conferre.gr

E-tegra[®]
Stent Graft System


The new generation
AAA endograft



Durable -
active fixation and 3D flexibility
for long therapeutic success

E-xtra[®] DESIGN ENGINEERING

Individuality -
custom-made in just
18 working days



ΜΑΚΡΑ ΠΡΟΣΤΑΣΙΑ
ΧΡΟΝΟΥ 18 ΗΜΕΡΩΝ

18

VenoSteam[™]

Injection -
micro pulses of steam directly into the vein
to ensure its obstruction
and loss of functionality



Verma
VEIN

MEDICAL
Horizons

JOTEC[®]

Φανερωμένης 30 & Ουρανίας 1, 155 62, Χολαργός
Τηλ: +30 210 6560660, 6538530, Fax: +30 210 6534721, E-mail: grammateia@medicalhorizons.gr



Bolton Medical

A WerfenLife Company

ADVANCE
into the next
EVAR level



 **TREOVANCE**[®]
Abdominal Stent-Graft with **Navitel**[™] Delivery System

cana
LABORATORIES

Registration Fees (euro/incl. VAT 23%)	
Registration Category	Onsite Registration
Doctors ¹	200,00 €
Trainees ¹	Free
Nursing Staff ²	Free
Students ³	Free

Registration for the Symposium

1. Registration Fee for Doctors and Trainees includes:

- Admission to the main Scientific Sessions
- Admission to the exhibition
- Symposium Material (badge, delegate bag, final programme, etc)
- Certificate of Attendance
- Coffee breaks and lunches during the Symposium
- Opening Ceremony and Welcome Reception

2. Registration Fee for Nursing Staff includes:

- Admission to the Vascular Nursing Session on Saturday, May 23th, 2015
- Admission to the exhibition
- Certificate of Attendance

3. Registration Fee for Students includes:

- Admission to the main Scientific Sessions
- Admission to the exhibition
- Certificate of Attendance

Receipts and Invoices

Receipts and Invoices for Registration, Accommodation & other expenses paid to Conferre Ltd for individual services will be provided to participants during the Symposium by the Secretariat, upon request.

Invoices to companies will be issued and sent after the symposium.

Registration for the Pre-Symposium Course

PRE-SYMPOSIUM COURSE

*Jointly organized with the European Society
for Vascular Surgery (ESVS)*

Modern Therapeutic Interventions in Venous Diseases

Thursday, May 21, 2015

09.00-15.30 hrs

Convenor: **Cees Wittens (The Netherlands)**

Registration Fee (euro/incl. VAT 23%):

€30,00 (for Doctors & Trainees)

Max participants:

42 pax

Important Notes for the Pre-Symposium Courses:

- **ONLY** doctors & trainees are entitled to participate.
- PRE-REGISTRATION is required.
- Registration for the Symposium does not presuppose registration for the Pre-Symposium Courses.
- Registrations will be honored on a first-come first-served space available basis.
- Registrations will be accepted until the maximum number of participants (of each) is reached.



European Union of Medical Specialists

EACCME - European Accreditation Council for Continuing
Medical Education Institution of the UEMS
Avenue de la Couronne 20, B-1050, Brussels

T: +32 2 649 5164 | F: +32 2 640 37 30 | E: accreditation@uems.net

The Institute of Vascular Diseases (IVD), Greece (or) LIVE 2015 - Leading Innovative Vascular Education' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The LIVE 2015 - Leading Innovative Vascular Education is designated for a maximum of (or for up to) **17 hours** of European external CME credits.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

AMA recognized credits

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Allocation of CME Credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on **1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.**



NELIIX[®]
Endovascular Aneurysm Sealing System

EVAS The New Paradigm in AAA Therapy

Treat More Patients¹

Includes complex EVAR cases² and iliac aneurysms

Simplify Procedure Planning

*Minimal product selection parameters,
more predictable procedure times³*

Designed to Reduce Secondary Interventions

Mitigates endoleaks of all types

www.endologix.com/nelix

1. Korthelmeijer A, et al. for J Vasc Med Biol. 2013;45:440-445.
2. Compare EVAR cases refer to EVAR with multiple zones for iliac aneurysm, neck, and/or short aorta.
3. M. Thompson, CA Symposium 2013. Data on file at Endologix, Inc.

The Neliix[®] Endovascular Aneurysm Sealing System, prior to use, refer to the instructions for use for details and specific instructions for identification, all warnings and precautions. © 2013 Endologix, Inc. All other trademarks are the property of their respective owners. Endologix, Inc. All rights reserved. 4840011 Rev. 12

ENDOLOGIX
Innovation that Empowers

PLUSMEDICA
TECHS2LIFE.com

Oral & e-Poster Presentations Sessions

Please note that all submitted abstracts were reviewed by an independent abstract **Review Committee** that was blinded in regard of authors' names and affiliations. The review, evaluation and final acceptance was based on the **best scoring** as far as work's scientific/clinical importance, results/conclusions & originality is concerned.

For the Presentation

All presenters are kindly requested to provide their presentations (**PowerPoint format in a USB-flash/disk/CD-ROM**) to the technical support personnel at least one (1) hour before the beginning of the Session (*in order to ensure on time their presentations run smoothly and to be able of making any possible changes*).

Duration

Oral Presentations (12 min in total)

Each oral presentation should not exceed **8 minutes**.
It will be followed by **4 minutes discussion**.

e-Poster Presentations (5 min in total)

Each e-poster presentation should not exceed **3 minutes**.
It will be followed by **2 minutes discussion**.

Presenters need to be strictly consisted with the time slots and to respect the flow of the scientific programme.

Awards

During the Opening Ceremony, the best Oral & the best e-Poster Presentations will be AWARDED by an independent scientific Award Committee (on the basis of scientific merit of authors' works and presentations).

Presenters should bear in mind that their presence during the Opening Ceremony is required for the award nomination procedure.

e-Abstract Book

All oral & e-poster presentations of LIVE 2015 will be included in the symposium e-Abstract Book.

ORAL PRESENTATIONS SESSION

OP01

DO STATINS STABILIZE HUMAN CAROTID PLAQUES IN PATIENTS UNDERGOING CAROTID ENDARTERECTOMY?

¹ G. Galyfos, ¹ D. Karageorgiadi, ¹ K. Filis, ² P. Efentakis,
¹ D. Tsilimigras, ³ E. Stroumpouli, ² D. Farmakis, ⁴ E.K. Iliodromitis,
² I. Andreadou, ¹ F. Sigala

¹ *First Department of Propaedeutic Surgery, University of Athens Medical School, Hippocraton Hospital, Athens, Greece;*

² *Department of Pharmaceutical Chemistry, University of Athens School of Pharmacy, Athens, Greece;*

³ *Department of Radiology, Hippocraton Hospital, Athens, Greece;*

⁴ *Second Department of Cardiology, University of Athens Medical School, Attikon Hospital, Athens, Greece;*

OP02

INFLOW STENOSIS INDUCED BY THE INFLATABLE RINGS OF THE OVATION ENDOGRAFT AND RESULTS OF ROUTINE USE OF AN AORTIC BALLOON

¹ N. Kontopodis, ² D. Tsetis, ³ E. Metaxa, ¹ D. Pantidis, ¹ E. Tavlas,
³ Y. Papaharilaou, ¹ C. Ioannou

¹ *Vascular Surgery Unit, Department of Cardiothoracic & Vascular Surgery, University of Crete Medical School, University Hospital of Heraklion, Crete, Greece;*

² *Interventional Radiology Unit, Department of Radiology, University of Crete Medical School, University Hospital of Heraklion, Crete, Greece;*

³ *Institute of Applied and Computational Mathematics, Foundation for Research and Technology-Hellas (FORTH), Crete, Greece;*

OP03

RAPID PROTOTYPING OF AORTA FOR IN VITRO STUDIES

¹ P. Bangeas, ¹ K. Kofina, ¹ M. Jahnic, ¹ D. Lycopoulos,
¹ K. Ktenidis

¹ *Vascular Surgery Department, 1st Propedeutical Surgery Clinic, AHEPA General Hospital, Aristotle University of Thessaloniki;*

ORAL PRESENTATIONS SESSION

OP04

POST IMPLANTATION INFLAMMATORY RESPONSE AFTER EVAR FOR AAA. INFLUENCE ON PATIENTS' ONE-YEAR OUTCOME

¹ E. Arnaoutoglou, ² G. Kouvelos, ² N. Papa, ³ K. Gartzonika, ⁴ H. Millionis, ⁵ V. Koulouras, ² M. Matsagkas

¹ Department of Anesthesiology, School of Medicine, University of Ioannina, Ioannina, Greece;

² Department of Surgery - Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece;

³ Laboratory of Immunology and Microbiology, School of Medicine, University of Ioannina, Ioannina, Greece;

⁴ Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece;

⁵ Department of Intensive Care Medicine, Medical School, University of Ioannina, Ioannina, Greece;

OP05

HEMODYNAMIC PROPERTIES AND PATTERNS BEFORE AND AFTER ENDOVASCULAR ANEURYSM REPAIR USING THE NELLIX (TM) ENDOVASCULAR SYSTEM

¹ A. Raptis, ² M. Xenos, ³ E. Georgakarakos, ¹ G. Kouvelos, ¹ M. Matsagkas

¹ Department of Surgery-Vascular Surgery Unit, Medical School, University of Ioannina, Ioannina, Greece;

² Department of Mathematics, University of Ioannina, Ioannina, Greece;

³ Department of Vascular Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;

OP06

ROLE OF VASCULAR RESECTION IN PANCREATIC TUMOR SURGERY

¹ P. Bangeas, ¹ S. Salonikidis, ¹ S. Abu Farha, ¹ T. Boutsiadou, ¹ D. Lykopoulos, ¹ K. Ktenidis

¹ Vascular Surgery Department, 1st Propedeutical Surgery Clinic, AHEPA General Hospital, Aristotle University of Thessaloniki;

ORAL PRESENTATIONS SESSION

OP07

PACLITAXEL-COATED BALLOON ANGIOPLASTY TREATMENT FOR THE FAILING DIALYSIS ACCESS. A 5-YEAR, REAL-LIFE EXPERIENCE

¹ P. Kitrou, ¹ S. Spiliopoulos, ¹ V. Theodosiadou, ¹ P. Papadimitos, ¹ N. Christeas, ¹ D. Karnabatidis

¹ Diagnostic and Interventional Radiology Department, Patras University Hospital, Patras, Greece;

OP08

THE EFFECT OF STENT DESIGN ON THIRTY-DAY OUTCOME AFTER CAROTID ARTERY STENTING: A META-ANALYSIS OF 8018 PATIENTS

¹ G. Kouvelos, ² N. Patelis, ³ G. Antoniou, ⁴ A. Lazaris, ¹ M. Matsagkas

¹ Department of Surgery-Vascular Surgery Unit, Medical School, University of Ioannina, Ioannina, Greece;

² First Department of Surgery- Vascular Surgery Unit, Medical School, University of Athens, Athens, Greece;

³ Liverpool Vascular and Endovascular Service, Royal Liverpool University Hospital, Liverpool, UK;

⁴ Third Department of Surgery-Vascular Surgery Unit, University of Athens, Athens, Greece;

OP09

TOTALLY PERCUTANEOUS ENDOVASCULAR ANEURYSM REPAIR USING THE PERCLOSE PROGLIDE DEVICE AND A PRE-CLOSING TECHNIQUE. SINGLE CENTER EXPERIENCE

¹ N. Kontopodis, ² D. Tsetis, ² E. Kehagias, ¹ N. Daskalakis,

² N. Galanakis, ¹ G. Papadopoulos, ¹ A. Kafetzakis, ¹ C. Ioannou

¹ Vascular Surgery Unit, Department of Cardiothoracic & Vascular Surgery, University of Crete Medical School, University Hospital of Heraklion, Crete, Greece;

² Interventional Radiology Unit, Department of Radiology, University of Crete Medical School, University Hospital of Heraklion, Crete, Greece;

ORAL PRESENTATIONS SESSION

OP10

ENDURANT (TM) VS EXCLUDER®: COMPARISON OF BLOOD FLOW PROPERTIES BETWEEN PATIENT-SPECIFIC MODELS USING COMPUTATIONAL FLUID DYNAMICS

¹ A. Raptis, ² M. Xenos, ³ E. Georgakarakos, ¹ G. Kouvelos,

¹ M. Matsagkas

¹ *Department of Surgery-Vascular Surgery Unit, Medical School, University of Ioannina, Ioannina, Greece;*

² *Department of Mathematics, University of Ioannina, Ioannina, Greece;*

³ *Department of Vascular Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;*

**ΕΠΩΝΥΜΟ
ΕΛΛΗΝΙΚΟ
ΦΑΡΜΑΚΟ**

Clovelen®

Κλοπιδογρέλη

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Clovelen® 75 mg επικαλυμμένα με λεπτό υμένιο δισκία. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ: Κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 75mg cloridogrel (κλοπιδογρέλης), ως besilate. Έκδοχα: κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 2.6mg μονοϋδρικής λακτόζης.

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.

Με την εγγύηση της



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,
Τηλ.: 210 6039326-9, Fax: 210 6039300

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα,
Τηλ.: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ.: 2310 459920-1, Fax: 2310 459269

e-POSTER PRESENTATIONS SESSION

ePP01

VASCULAR TRAUMA MANAGEMENT IN AN URBAN TRAUMA CENTRE: A 20 YEAR EXPERIENCE

¹ G. Galyfos, ¹ G. Kastrisios, ¹ S. Kerasidis, ¹ G. Stamatatos,

¹ G. Stefanidis, ¹ G. Papacharalampous, ¹ C. Maltezos

¹ *Department of Vascular Surgery, KAT General Hospital, Athens, Greece;*

ePP02

ENDOVASCULAR OPTIONS TO TREAT SPLENIC ARTERY ANEURYSMS: CASE REPORT, CONSIDERATIONS AND EARLY RECOMMENDATIONS

¹ D. Papadimitriou, ² E. Perdikakis, ² G. Zimbidis

¹ *Vascular & Endovascular Department, 424 Military Hospital, Nea Eukarpia, Thessaloniki, Greece;*

² *Department of Interventional Radiology, 424 General Military Hospital, Nea Eukarpia, Thessaloniki, Greece;*

ePP03

INTERACTION OF NANOMEDICINE WITH CONVENTIONAL VASCULAR SURGERY

¹ P. Bangeas, ¹ P. Goulas, ¹ M. Jahnic, ¹ D. Lykopoulos,

¹ K. Ktenidis

¹ *Vascular Surgery Department, 1st Propedeutical Surgery Clinic, AHEPA General Hospital, Aristotle University of Thessaloniki;*

ePP04

EARLY AND LATE COMPLICATIONS AFTER ENDOVASCULAR REPAIR OF ABDOMINAL AORTIC ANEURYSM: SUPRARENAL VERSUS INFARENAL FIXATION

¹ G. Stamatatos, ¹ G. Galyfos, ¹ S. Giannakakis, ¹ S. Kerasidis,

¹ G. Stefanidis, ¹ G. Geropapas, ¹ G. Papacharalampous,

¹ C. Maltezos

¹ *Department of Vascular Surgery, KAT General Hospital, Athens, Greece;*

e-POSTER PRESENTATIONS SESSION

ePP05

EFFICACY, SAFETY AND DURABILITY OF DIRECT STENTING IN PATIENTS WITH ACUTE LOWER LIMB ARTERIAL OCCLUSIONS. LONG TERM RESULTS

¹ N. Galanakis, ¹ I. Peteinarakis, ¹ E. Kehagias, ² N. Kontopodis, ² C. Ioannou, ¹ D. Tsetis

¹ *Interventional Radiology Unit, Department of Radiology, University Hospital of Heraklion, Heraklion, Greece;*

² *Vascular Surgery Unit, Department of Cardiothoracic and Vascular Surgery, University Hospital of Heraklion, Heraklion, Greece;*

ePP06

ASSESSMENT OF THE DELETERIOUS ROLE OF THE INTRALUMINAL THROMBUS IN A RAT MODEL OF ABDOMINAL AORTIC ANEURYSM: ROLE OF AN ANTI-THROMBOXANE RECEPTOR

^{1,2} A. Courtois, ³ A. Nchimi, ^{1,4} A. Arbesu Y Miar, ⁵ P. Drion,

^{1,2} J.-P. Cheramy-Bien, ⁴ J.-M. Dogné, ² J.-O. Defraigne,

^{2,1} N. Sakalihan

¹ *Surgical Research Center, GIGA-Cardiovascular Unit, University of Liège, Belgium;*

² *Department of Cardiovascular Surgery, University Hospital Liège, Belgium;*

³ *Department of Medical Imaging, University Hospital Liège, Belgium;*

⁴ *Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Belgium;*

⁵ *Department of Experimental Surgery and Animal Care, University Hospital Liège, Belgium;*

ePP07

VENOPLASTY AND STENTING TO TREAT OBSTRUCTION OF THE RIGHT INNOMINATE VEIN IN A YOUNG PATIENT. ARE VEIN PATHOLOGIES A NEW FIELD IN ENDOVASCULAR PROCEDURES?

¹ D. Papadimitriou, ² E. Perdikakis, ² G. Zimilidis

¹ *Vascular & Endovascular Department, 424 General Military Hospital, Thessaloniki, Greece;*

² *Department Of Interventional Radiology, 424 General Military Hospital, Thessaloniki, Greece;*



e-POSTER PRESENTATIONS SESSION

ePP08

CONCOMITANT ATHEROSCLEROTIC LESIONS OF THE AORTIC ARCH BRANCHES AND LOWER EXTREMITIES ARTERIES: DIAGNOSES, LESIONS SEVERITY AND SURGICAL TREATMENT

J.G. Sobirov, V.Sh. Bakhritdinov

¹ *Vascular surgery department, Republican Specialized Center of Surgery named after acad. V.Vakhidov, Tashkent, Uzbekistan;*

ePP09

ANTITHROMBOTIC THERAPY IN CAROTID ARTERY STENTING AND CAROTID ENDARTERECTOMY WITHIN THE ASYMPTOMATIC CAROTID SURGERY TRIAL-2 (ACST-2)

^{1,3} A. Huibers, ² R. Bulbulia, ³ G.J. de Borst, ¹ A. Halliday

¹ *Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;*

² *Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom;*

³ *Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands;*

ePP10

A NOVEL TECHNIQUE FOR THORACIC AORTA ANEURYSM REPAIR IN A PATIENT WITH A SOLITARY KIDNEY

¹ C. Bakoyiannis, ¹ D. Moris, ¹ G. Karaolani, ¹ N. Patelis,

¹ A. Maskanakis, ¹ G. Tsaples, ¹ C. Klonaris, ¹ S. Georgopoulos

¹ *Vascular Division, 1st Dept of Surgery, Laiko General Hospital, National Kapodistrian University of Athens;*

ePP11

USE OF PARALLEL GRAFTS TO TREAT PARARENAL OR TYPE IV THORACOABDOMINAL ANEURYSMS. CAN WE ACHIEVE GOOD GRAFT STABILITY? A LABORATORY APPROACH

^{1,2} D. Papadimitriou, ² M. Lachat, ² D. Mayer, ² Z. Rancic

¹ *Vascular & Endovascular Department, 424 Military Hospital, Thessaloniki, Greece;*

² *Cardiovascular Clinic, Department of Vascular Surgery, Zurich University Hospital, Zurich, Switzerland;*

e-POSTER PRESENTATIONS SESSION

ePP12

EARLY SINGLE-CENTRE EXPERIENCE WITH NELLIX EVAS SYSTEM

² M. Doulaptis, ¹ N. Patelis, ² A. Kotzadimitriou, ¹ A. Maskanakis, ¹ G. Karaolani, ¹ G. Tsaples, ¹ C. Bakoyiannis, ¹ S. Georgopoulos, ¹ C. Klonaris

¹ *Vascular Division, 1st Dept of Vascular Surgery, Laiko General Hospital, National Kapodistrian University of Athens;*

² *Vascular Division, 2nd Propeudetic Dept of Vascular Surgery, Laiko General Hospital, National Kapodistrian University of Athens;*

ePP13

THROMBIN INJECTION OF IATROGENIC FEMORAL PSEUDOANEURYSM AND IPSILATERAL DEEP VEIN THROMBOSIS DUE TO FEMORAL COMPRESSION: A THERAPEUTIC DILEMMA?

¹ M. Papadakis, ¹ N. Floros

¹ *Department of Vascular Surgery, University Hospital Witten-Herdecke, HELIOS Klinikum Wuppertal;*

ePP14

MANAGEMENT OF VASCULAR GRAFT INFECTIONS-CASE SERIES

¹ P. Bangeas, ² S. Salonikidis, ¹ A. Giannopoulos, ¹ D. Lykopoulos, ² D. Paramythiotis, ² G. Basdanis, ¹ K. Ktenidis

¹ *Vascular Surgery Department, 1st Propedeutical Surgery Clinic, AHEPA General Hospital, Aristotle University of Thessaloniki;*

² *1st Propedeutical Surgery Clinic, AHEPA General Hospital, Aristotle University of Thessaloniki;*

ePP15

DIFFERENTIAL APPROACH TO THE TREATMENT OF THE PATIENTS WITH ATHEROSCLEROTIC LESION OF AORTO-FEMORAL SEGMENT HAVING STENOSIS AND OCCLUSIVE DISEASE SIMALTANEOUSLY

¹Y. Hardubey

¹*Kherson City Clinical Hospital "E.E. Karabelesh", Kherson, Ukraine*

e-POSTER PRESENTATIONS SESSION

ePP16

ASSESSMENT OF KNOWLEDGE AND ATTITUDES TOWARDS HIV / AIDS NURSING PERSONNEL VLORE

¹ G. Sinanaj, ¹ A. Harxhi, ² M. Nakuci, ² B. Miftari, ¹ B. Subashi, ¹ R. Luci, ¹ D. Selfo

¹ Faculty of Public Health, University "Ismail Qemali" Vlore;

² Hospital Center "Mother Teresa" Tirana;

ePP17

ANTEGRADE EVERSION ENDARTERECTOMY OF THE EXTERNAL ILIAC ARTERY FOR THE TREATMENT OF EXTERNAL ILIAC ARTERY ENDOFIBROSIS. A CASE REPORT

¹ S. Theodorou, ¹ T. Konstantopoulos, ¹ G. Galanopoulos,

¹ I. Tsoutsas, ¹ D. Xanthopoulos, ¹ E. Kaperonis, ¹ K. Loupou,

¹ S. Tsoupanos, ¹ V. Papavasiliou

¹ Department of Vascular Surgery, "Sismanoglio-A.Fleming" General Hospital, Marousi, Greece;

ePP18

ENDOLUMINAL TREATMENT OF STANFORD TYPE B AORTIC DISSECTION WITH PROXIMAL ENTRY TEAR REPAIR

¹ N. Asaloumidis, ² G. Trellopoulos, ¹ C. Karkos, ¹ K. Konstantinidis,

¹ I. Giagtzidis, ¹ K. Papazoglou,

¹ E' Surgery, Vascular Surgery, General Hospital "Ippokrateion," Thessaloniki, AUTH, Greece;

² Vascular Surgery, General Hospital "Papanikolaou," Thessaloniki, NHS, Greece;

ePP19

THE EFFECT OF INCREASING OPERATOR EXPERIENCE ON PROCEDURE-RELATED CHARACTERISTICS IN PATIENTS UNDERGOING CAROTID ARTERY STENTING

¹ G. Kouvelos, ¹ A. Koutsoumpelis, ² E. Arnaoutoglou, ¹ V. Bouris, ¹ M. Peroulis, ² G. Papadopoulos, ¹ M. Matsagkas

¹ Department of Surgery-Vascular Surgery Unit, University of Ioannina, Medical School, Ioannina, Greece;

² Department of Anesthesiology, University of Ioannina, Medical School, Ioannina, Greece;

e-POSTER PRESENTATIONS SESSION

ePP20

THE ROLE OF CALPROTECTIN IN ABDOMINAL AORTIC ANEURYSM DEVELOPMENT AND PROGRESSION IN RATS. A PORCINE PANCREATIC ELASTASE-INDUCED EXPERIMENTAL MODEL

¹ D. Moris, ² I. S. Vlachos, ³ G. Agrogiannis, ¹ C. Bakoyiannis,

² D. N Perrea, ¹ S. Georgopoulos

¹ *First Department of Surgery, Vascular Unit, "Laikon" General Hospital, National and Kapodistrian University of Athens, Athens, Greece;*

² *Laboratory for Experimental Surgery and Surgical Research "N.S. Christeas", Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece;*

³ *Division of Pathology, National and Kapodistrian University of Athens, Athens, Greece;*

ePP21

ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR (EVAR) IN A TWICE CROSSED-LIMB "DOUBLE BALLERINA" CONFIGURATION. A CASE REPORT

¹ S. Theodorou, ¹ T. Konstantopoulos, ¹ G. Galanopoulos,

¹ I. Tsoutsas, ¹ D. Xanthopoulos, ¹ E. Kaperonis, ¹ K. Loupou,

¹ S. Tsoupanos, ¹ V. Papavasiliou

¹ *Department of Vascular Surgery, "Sismanoglio-A.Fleming" General Hospital, Marousi, Greece;*

ePP22

LATE RESULTS OF A CHALLENGING TEVAR IN A COMPLICATED ACUTE TYPE B AORTIC DISSECTION IN A PATIENT WITH PRIOR EVAR TREATMENT

¹ M. Moustardas, ² P. Korakas

¹ *Vascular Department, Iasis Hospital, Chania, Greece;*

² *Radiology Department, General Hospital of Chania "O Agios Georgios", Chania Greece;*

e-POSTER PRESENTATIONS SESSION

ePP23

AN UNUSUAL CASE OF ACUTE THROMBOSIS OF ABDOMINAL AORTIC ANEURYSM WITHOUT ACUTE LIMB ISCHEMIA

¹ S. Mastoraki, ¹ K. Moulakakis, ¹ A. Lazaris, ¹ S. Vasdekis

¹ *Department of Vascular Surgery, Athens University Medical School, "Attikon" Hospital, Athens, Greece;*

ePP24

SHORT TERM OUTCOMES OF INTRODUCING PERCUTANEOUS ENDOVASCULAR ANEURYSM REPAIR IN COMPARISON TO OPEN ENDOVASCULAR ANEURYSM REPAIR AT AN ACADEMIC INSTITUTION

^{1,2} B. Chan, ² V. Srivatsav, ^{1,2} F. Elias, ¹ T. Adrinopoulos, ^{1,2} D. Szalay, ^{1,3} J. Tittley, ³ J. Harlock, ^{1,2} T. Rapanos

¹ *Division of Vascular Surgery, Hamilton Health Sciences, Hamilton, Canada;*

² *McMaster University, Hamilton, Canada;*

³ *Hamilton Health Sciences, McMaster University;*

ePP25

TYPE B AORTIC ARCH INTERRUPTION IN THE YOUNGS. SINGLE CENTER CREATIVE EXPERIENCE

¹ Y. Kolesnikov, ¹ V. Arakelyan

¹ *Department of Arterial Diseases, Bakoulev A.N. Scientific Center for Cardiovascular Surgery of the Russian Academy of Medical Sciences, Moscow, Russia;*

ePP26

PREDICTING EARLY GRAFT FAILURE AFTER INFRAINGUINAL SURGICAL REVASCULARIZATION: DEVELOPMENT AND INTERNAL VALIDATION OF A RISK-SCORING SYSTEM

¹ A. Lazaris, ¹ S. Mastoraki, ¹ M. Karouki, ¹ K. Seretis, ¹ S. Vasdekis

¹ *Department of Vascular Surgery, Athens University Medical School, "Attikon" Hospital, Athens, Greece;*

e-POSTER PRESENTATIONS SESSION

ePP27

**INVESTIGATION OF GRAVITY OF THORACIC AORTIC
ATHEROSCLEROSIS COMPARED TO AGE, SEX AND
PRESENCE OF THROMBOUS IN LEFT ATRIAL APPENDAGE**

¹ G. Spyromitros, ¹ I. Lagos

¹ *Cardiology Department, General Hospital of Katerini, Katerini, Greece;*

ePP28

**RE-ROOTING OF THE AORTIC ARCH AND ENDOVASCULAR
REPAIR FOR THE TREATMENT OF ARCH PATHOLOGIES**

¹ F. Eforakopoulos, ² Ch. Kalogeropoulou, ² P. Zambakis,

¹ E. Koletsis, ¹ C. Prokakis, ¹ N. Charoulis, ³ A. Sambalioti,

³ F. Fligou, ¹ Ch. Stroubos, ¹ P. Papadopoulos, ¹ P. Alexopoulos,

¹ M. Margaritis, ¹ A. Kizilis, ¹ D. Dougenis

¹ *Department of Cardiothoracic Surgery, School of Medicine, University of Patras, Patras, Greece*

² *Department of Radiology, School of Medicine, University of Patras, Patras, Greece*

³ *Department of Anesthesiology and Intensive Care Medicine, School of Medicine, University of Patras, Patras, Greece*



innohep[®]

Ελεύθεροι να εστιάσετε

innohep[®]
tinzaparin sodium

“Δεν θέλω και άλλες έγνοιες.
Η μάχη με τον καρκίνο
είναι αρκετή”

LEO[®]

Για τις πλήρεις συνταγογραφικές πληροφορίες επικοινωνήστε με την:

LEO Pharma Hellas S.A

Λ. Κύμης & Σενέκα 10, 145 64 - Κηφισιά, Τηλ. 212 2225000, fax. 210 6834342.

Γραφείο Βορείου Ελλάδος: 10^ο χλμ Θεσσαλονίκης - Θέρμης, Balkan Center, 570 01- Θεσσαλονίκη,
Τηλ. 2310 989221, Fax. 2310 989236, <http://www.leo-pharma.gr>



innohep®

1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: innohep® 10.000 anti Xa IU/0,5ml PF.SYR. Ενέσιμο διάλυμα. innohep® 14.000 anti Xa IU/0,7ml PF.SYR. Ενέσιμο διάλυμα. innohep® 18.000 anti Xa IU/0,9ml PF.SYR. Ενέσιμο διάλυμα. **2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Tinzaparin sodium 20.000 anti-Xa IU/ml. Έκδοχα με γνωστές δράσεις: Sodium metabisulphite (1,83 mg/ml) και η ολική ποσότητα νατρίου είναι μικρότερη από 1 mmol νάτριο (23 mg) ανά δόση, όπλ. ουσιαστικά είναι «ελεύθερο νάτριο». **4.3. Αντενδείξεις:** Ενεργός ή ιστορικό ανοσολογικής επαγόμενης από ηπαρίνη θρομβοκυτοπενία (τύπου II) (βλέπε παράγραφο 4.4). Ενεργή μείζονα αιμορραγία ή συνθήκες που προδιαθέτουν για μείζονα αιμορραγία. Μείζονα αιμορραγία ορίζεται όταν πληροί οποιαδήποτε από αυτά τα τρία κριτήρια: α) συμβαίνει σε μία σημαντική περιοχική ή όργανο (π.χ. ενδοκρανιακή, ενδορραχιαία, ενδοφθάλμια, οπισθοπεριτοναϊκή, ενδοαρθρική ή περικαρδιακή, ενδομυϊκή ή ενδομυϊκή με σύνδρομο διαμερίσματος, β) προκαλεί πτώση του επιπέδου αιμοσφαιρίνης της τάξης των 20 g/L (1,24 mmol/L) ή περισσότερο, γ) οδηγεί σε μετάγγιση δύο ή περισσότερων μονάδων πλήρους αίματος ή ερυθρών κυττάρων. Σηπτική ενδοκαρδίτιδα. Οι θεραπευτικές δόσεις του innohep® (175 IU/kg) αντενδείκνυνται σε ασθενείς που λαμβάνουν νευραζονική αναισθησία. Εάν έχει προγραμματιστεί νευραζονική αναισθησία, το innohep® θα πρέπει να διακοπεί τουλάχιστον 24 ώρες πριν την εκτέλεση της διαδικασίας. Το innohep® δεν θα πρέπει να επαναχορηγηθεί νωρίτερα από τουλάχιστον 4-6 ώρες μετά τη χρήση της νωτιαίας αναισθησίας ή μετά την αφαίρεση του καθετήρα. Οι ασθενείς θα πρέπει να παρακολουθούνται στενά για σημεία ή συμπτώματα νευρολογικής βλάβης. **4.4. Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** Νευροεγκενική αναισθησία [για τις προφυλακτικές ενδείξεις μόνο]. Συνιστάται προσοχή όταν πραγματοποιείται νευραζονική αναισθησία ή σφαιρική παρακέντηση σε ασθενείς που λαμβάνουν προφυλακτικές δόσεις innohep®, λόγω του κινδύνου νωτιαίου αιματώματος το οποίο μπορεί να προκαλέσει παρατεταμένη ή και μόνιμη παράλυση. Θα πρέπει να μετριοπαθεί ελάχιστη καθυστέρηση 12 ωρών μεταξύ της χορήγησης της τελευταίας προφυλακτικής δόσης και της τοποθέτησης βελόνας ή καθετήρα. Για συνεχείς τεχνικές, ανάλογη καθυστέρηση θα πρέπει να εφαρμόζεται και πριν την αφαίρεση του καθετήρα. Επιπλέον, η επαναχορήγηση του innohep® δεν θα πρέπει να αρχίζει νωρίτερα από τουλάχιστον 4-6 ώρες μετά τη χρήση της νωτιαίας αναισθησίας ή μετά την αφαίρεση του καθετήρα. Οι ασθενείς θα πρέπει να παρακολουθούνται στενά για σημεία ή συμπτώματα νευρολογικής βλάβης. **Αιμορραγία:** Συνιστάται προσοχή όταν το innohep® χορηγείται σε ασθενείς με κίνδυνο αιμορραγίας. Για ασθενείς που διατρέχουν κίνδυνο μείζονος αιμορραγίας βλέπε παράγραφο 4.3. Ο συνδυασμός με φαρμακευτικά προϊόντα που επηρεάζουν τη λειτουργία των αιμοπεταλίων ή του συστήματος πήξης θα πρέπει να αποφεύγεται ή να παρακολουθείται προσεκτικά (βλέπε παράγραφο 4.5). **Ενδομυϊκές ενέσεις:** Το innohep® δεν πρέπει να χορηγείται με ενδομυϊκή ένεση εξ' αιτίας του κινδύνου δημιουργίας αιματώματος. Εξ' αιτίας του κινδύνου δημιουργίας αιματώματος, η ταυτόχρονη χρήση ενδομυϊκών ενέσεων θα πρέπει να αποφεύγεται. **Θρομβοκυτοπενία επαγόμενη από ηπαρίνη:** Εξ' αιτίας του κινδύνου εμφάνισης ανοσολογικής θρομβοκυτοπενίας επαγόμενης από ηπαρίνη (τύπου II), θα πρέπει να μετράται ο αριθμός των αιμοπεταλίων πριν την έναρξη της θεραπείας και περιοδικά στη συνέχεια. Το innohep® πρέπει να διακόπτεται σε ασθενείς που αναπτύσσουν ανοσολογική θρομβοκυτοπενία επαγόμενη από ηπαρίνη (τύπου II) (βλέπε παράγραφο 4.3 και 4.8). Ο αριθμός των αιμοπεταλίων συνήθως θα ομαλοποιείται εντός 2 έως 4 εβδομάδων μετά τη διακοπή. **Υπερκαλιαιμία:** Τα προϊόντα ηπαρίνης μπορεί να καταστείλουν την επινεφριδιακή έκκριση αλδοστερόνης που οδηγεί σε υπερκαλιαιμία. Στους παράγοντες κινδύνου περιλαμβάνονται ασθενείς με σακχαρώδη διαβήτη, χρόνια νεφρική ανεπάρκεια, προϋπάρχουσα μεταβολική αζέμια, αυξημένο κάλιο του ορού πριν την έναρξη της θεραπείας, ταυτόχρονη θεραπεία με φάρμακα τα οποία μπορεί να αυξήσουν το επίπεδο καλίου στο πλάσμα, και μακροχρόνια χρήση του innohep®. Σε ασθενείς που διατρέχουν κίνδυνο, θα πρέπει να μετρούνται τα επίπεδα του καλίου πριν την έναρξη του innohep® καθώς και να παρακολουθούνται τακτικά επί συνείκεια. Η υπερκαλιαιμία που σχετίζεται με την ηπαρίνη είναι συνήθως αναστρέψιμη μετά τη διακοπή της θεραπείας, ωστόσο μπορεί να χρειαστεί να εξεταστεί η εφαρμογή άλλων μεθόδων εάν η θεραπεία με innohep® θεωρείται ζωτικής σημασίας (π.χ. μείωση της πρόσληψης καλίου, διακοπή άλλων φαρμάκων που μπορεί να επηρεάζουν την ισορροπία του καλίου). **Προβλεπόμενες καρδιακές βλάβες:** Δεν υπάρχουν επαρκείς μελέτες για να αξιολογηθούν την ασφαλή και αποτελεσματική χρήση του innohep® στην πρόληψη θρόμβωσης της βλάβης σε ασθενείς με προβλεπόμενες καρδιακές βλάβες. Η χρήση του innohep® δεν μπορεί να συνιστάται για το σκοπό αυτό. **Νεφρική βλάβη:** Τα διαθέσιμα στοιχεία δεν καταδεικνύουν συσσώρευση σε ασθενείς με επίπεδα κθάρασης της κρεατινίνης έως 20 mL/minute. Παρόλο που η παρακολούθηση των anti-Xa είναι η πιο κατάλληλη μέτρηση των φαρμακοδυναμικών επιδράσεων του innohep®, παραμένει ένας αδύνατος δείκτης πρόβλεψης του κινδύνου αιμορραγίας, παρ' όλα αυτά ο παρακολούθησις της δραστηριότητας του παράγοντος anti-Xa μπορεί να αξιολογηθεί σε ασθενείς με σοβαρή νεφρική βλάβη (κθάραση κρεατινίνης <30 mL/minute). Συνιστάται προσοχή κατά την θεραπεία ασθενών με σοβαρή νεφρική βλάβη (κθάραση κρεατινίνης <30 mL/minute). Υπάρχουν περιορισμένα διαθέσιμα δεδομένα σε ασθενείς με εκπιμώμενο επίπεδο κθάρασης της κρεατινίνης κάτω των 20 mL/minute. **Ηλικιωμένοι:** Οι ηλικιωμένοι είναι περισσότερο πιθανό να έχουν μειωμένη νεφρική λειτουργία. (βλέπε παράγραφο 4.4: Νεφρική βλάβη), συνεπώς θα πρέπει να δίνεται προσοχή όταν συνταγογραφείται το innohep® στους ηλικιωμένους. **Προειδοποιήσεις για τα έκδοχα:** Αυτό το φαρμακευτικό προϊόν περιέχει λιγότερο από 1 mmol νάτριο (23 mg) ανά δόση, όπλ. ουσιαστικά είναι «ελεύθερο νάτριο». Από τη μορφή του innohep® περιέχει μεταδιθειώδες νάτριο (sodium metabisulphite). Το μεταδιθειώδες νάτριο μπορεί πάντα να προκαλέσει σοβαρές αντιδράσεις υπερευαισθησίας και βρογχόσπασμο. Οι μορφές innohep® που περιέχουν μεταδιθειώδες νάτριο πρέπει να χρησιμοποιούνται με προσοχή σε ασθενείς με άσθμα. Επειδή οι παθίτες χαμηλού μοριακού βόρου εμφανίζουν μεταξύ τους διαφορές ως προς τον τρόπο παρασκευής τους, το μοριακό βάρος και την έκφραση της δραστηριότητάς τους, εισηγοιούνται ότι για αποφυγή λαθών κατά τη διάρκεια της θεραπευτικής αγωγής δεν θα πρέπει να γίνεται αλλαγή από ιδιοσκευάσμα της μιας εταιρείας σε ιδιοσκευάσμα της άλλης. **4.8. Ανεπιθύμητες ενέργειες:** Οι συχνότερα αναφερόμενες ανεπιθύμητες ενέργειες, είναι τα αιμορραγικά επεισόδια, δευτερογενής ανομία λόγω αιμορραγίας και αντιδράσεις στο σημείο της ένεσης. Αιμορραγία μπορεί να παρουσιαστεί σε οποιοδήποτε όργανο και να έχει διαφορετικούς βαθμούς βαρύτητας. Επιπλοκές μπορεί να παρουσιαστούν, ιδίως όταν χορηγούνται μεγάλες δόσεις. Παρόλο που οι μείζονες αιμορραγίες είναι ασυνήθεις, έχει αναφερθεί θάνατος ή μόνιμη ανικανότητα σε ορισμένες περιπτώσεις. Η ανοσολογική θρομβοκυτοπενία επαγόμενη από ηπαρίνη (τύπου II) εκδηλώνεται σε μεγάλο βαθμό μέσα σε 5 με 14 μέρες από τη λήψη της πρώτης δόσης. Επιπλέον, έχει περιγραφεί μία μορφή ταχείας εκδήλωσης σε ασθενείς οι οποίοι έχουν εκτεθεί κατά το παρελθόν στην ηπαρίνη. Η ανοσολογική θρομβοκυτοπενία επαγόμενη από ηπαρίνη (τύπου II) μπορεί να σχετίζεται με αρθρική και φλεβική θρόμβωση. Το innohep® πρέπει να διακόπτεται σε όλες τις περιπτώσεις ανοσολογικής θρομβοκυτοπενίας επαγόμενης από ηπαρίνη (βλέπε παράγραφο 4.4). Σε σπάνιες περιπτώσεις, το innohep® μπορεί να προκαλέσει υπερκαλιαιμία λόγω υποαλδοστερονισμού. Στους ασθενείς σε κίνδυνο περιλαμβάνονται αυτοί με σακχαρώδη διαβήτη ή νεφρική βλάβη (βλέπε παράγραφο 4.4). Σοβαρές αλλεργικές αντιδράσεις μπορεί να παρουσιαστούν σε ορισμένες περιπτώσεις. Αυτές περιλαμβάνουν σπάνιες περιπτώσεις νέκρωσης του δέρματος, τοξικό δερματικό εξάνθημα (π.χ. Stevens-Johnson syndrome), αγγειοοίδημα και αναφυλαξία. Η θεραπεία θα πρέπει να διακόπτεται άμεσα στην παραμικρή υποψία εμφάνισης τέτοιων σοβαρών αντιδράσεων. Ο υπολογισμός της συχνότητας των ανεπιθύμητων ενεργειών βασίζεται σε ανάλυση συγκεντρωμένων δεδομένων από κλινικές μελέτες και από αυθόρμητες αναφορές. Οι ανεπιθύμητες ενέργειες κατατάσσονται κατά MedDRA Κατηγορία Οργάνου Σύστημα (SOC) και οι μεμονωμένες ανεπιθύμητες ενέργειες ταξινομούνται ξεκιτώντας με τις πιο συχνά αναφερόμενες. Εντός κάθε κατηγορίας συκύντως εμφάνισης, οι ανεπιθύμητες αντιδράσεις αναφέρονται κατά φθίνουσα σειρά σοβαρότητας. Πολύ συχνές: $\geq 1/10$. Συχνές: $\geq 1/100$ και $< 1/10$. Όχι συχνές: $\geq 1/1.000$ και $< 1/100$. Σπάνιες: $\geq 1/10.000$ και $< 1/1.000$. Πολύ σπάνιες: $< 1/10.000$. **Διαταραχές του αιμοποιοτικού και του λεμφικού συστήματος:** Συχνές $\geq 1/100$ και $< 1/10$: Αναμία (συμπεριλαμβανομένης μείωσης της αιμοσφαιρίνης). Όχι συχνές $\geq 1/1.000$ και $< 1/100$: Θρομβοκυτοπενία (τύπου II), (συμπεριλαμβανομένης μείωσης αριθμού αιμοπεταλίων). Σπάνιες $\geq 1/10.000$ και $< 1/1.000$: Επαγόμενη από ηπαρίνη θρομβοκυτοπενία (τύπου II), θρομβοκυττάρωση. **Διαταραχές του ανοσοποιητικού συστήματος:** Όχι συχνές $\geq 1/1.000$ και $< 1/100$: Υπερευαισθησία. Σπάνιες $\geq 1/10.000$ και $< 1/1.000$: Αναφυλακτική αντίδραση. **Διαταραχές του μεταβολισμού και της θρέψης:** Σπάνιες $\geq 1/10.000$ και $< 1/1.000$: Υπερκαλιαιμία. **Αγγειακές διαταραχές:** Συχνές $\geq 1/100$ και $< 1/10$: Αιμορραγία, Αιμάτωμα. Όχι συχνές $\geq 1/1.000$ και $< 1/100$: Μυϊολιπόμιο, εκχύλιση και πορφύρα. **Διαταραχές του ήπατος και των χοληφόρων:** Όχι συχνές $\geq 1/1.000$ και $< 1/100$: Αυξημένο ηπατικό ένζυμο (συμπεριλαμβανομένων αυξημένων τρανσαμινασών, ALT, AST και GGT). **Διαταραχές του δέρματος και του υποδόριου ιστού:** Όχι συχνές $\geq 1/1.000$ και $< 1/100$: Δερματίτις (συμπεριλαμβανομένων αλλεργικής δερματίτιδας και πομφολυγώδους δερματίτιδας), Εξάνθημα, Κνίση. Σπάνιες $\geq 1/10.000$ και $< 1/1.000$: Τοξικό δερματικό εξάνθημα (συμπεριλαμβανομένου Stevens-Johnson syndrome), Νέκρωση του δέρματος, Αγγειοοίδημα, Κνίση. **Διαταραχές του μυοσκελετικού συστήματος και του συνδετικού ιστού:** Σπάνιες $\geq 1/10.000$ και $< 1/1.000$: Οστεοπόρωση (σε συνδυασμό με μακροχρόνια θεραπεία). **Διαταραχές του αναπαραγωγικού συστήματος και του μαστού:** Σπάνιες $\geq 1/10.000$ και $< 1/1.000$: Πριασμός. **Γενικές διαταραχές και καταστάσεις της οδού χορήγησης:** Συχνές $\geq 1/100$ και $< 1/10$: Αντίδρασης στο σημείο της ένεσης (συμπεριλαμβανομένων αιματώματος στο σημείο της ένεσης, αιμορραγίας, πόνου, κνησμού, οίδημο, ερυθρότητας και εξαγγελίωσης). Ασφαλή πιθανολογούμενες ανεπιθύμητες ενεργειών: Η αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών μετά από τη χορήγηση άδειας κυκλοφορίας του φαρμακευτικού προϊόντος είναι σημαντική. Επιπλέον η συνεχή παρακολούθηση της σχέσης οφέλους-κινδύνου του φαρμακευτικού προϊόντος. Ζητείται από τους επαγγελματίες του τομέα της υγείας να αναφέρουν σε οποιοδήποτε σημείο της υγειονομικής περιβαλλόντας να αναφέρουν οποιαδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες μέσω του εθνικού συστήματος αναφοράς που αναγράφεται στο Παράρτημα V. **7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** LEO Pharmaceutical Hellas S.A., Α. Κύμης & Ξενίας 10 - 145 64 Κηφισιά, ΤΗΛ. 2106834322.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «KITPINH KAPTA»



Bayer



Friday, May 22nd 2015
PASIPHAE HALL

12:05-13:05 SATELLITE SESSION
**Management of clinical cases
with Rivaroxaban**

Chairman: **A. Giannoukas**

Introduction

A. Giannoukas

Treating VTE with rivaroxaban; Presentation of clinical cases

M. Matsagkas

Perioperative management of rivaroxaban; Presentation of clinical cases

E. Arnaoutoglou

Discussion: **A. Giannoukas, M. Matsagkas,
E. Arnaoutoglou**



Friday, May 22nd 2015
PASIPHAE HALL

14:15-15:15 SATELLITE LUNCH SESSION

Chairman: **I. Tsolakis**

Overcoming Challenging Aortic Anatomy:
from Hostile Necks to Tortuous Iliac arteries

C. Maltezos

TEVAR in Acute Type B dissection

D. Dougenis

GORE® PROPATEN® Vascular Graft - 10 years data
and own experience

A. Giannoukas





Friday, May 22nd 2015
PASIPHAE HALL

15:30-16:00 SATELLITE SESSION

E-treatment "The usage of specific tools for the efficient management of aortic aneurysms"

Chairman: **I. Kakisis**

E-tegra: Just another AAA endograft?

D. Apostolou

E-liac: Experience from a branched graft for treating Aorto-iliac as well as isolated iliac Aneurysmal Disease

D. Apostolou

E-xtra Design: The importance of having a customized branched graft in your armamentarium

L. Lovato



Saturday, May 23rd 2015
PASIPHAE HALL

12:05-12:50 SATELLITE SESSION

Expanding EVAR safely

Chairman: **A. Giannoukas**

Protect the Neck - a proven sealing technology preserving the neck anatomy

A. Tassiopoulos

The value of PEVAR and the Ovation experience at Heraklion University Hospital

C. Ioannou

Selecting a workhorse system and the Ovation experience at Sismanoglio Hospital

N. Zannes



14:20-15:05 SATELLITE LUNCH SESSION
EVAS: New era in abdominal aneurism treatment

Chairmen: **M. Matsagkas, C. Klonaris**

The Nellix concept: From design to clinical practice

M. Cosimetti

Evidence from the EVAS Global registry

D. Krievens

Case presentation

C. Klonaris

Questions & Answers



17:30-18:00 SATELLITE LECTURE


Chairmen: **I. Tsolakis, K. Katsenis**

Is Tinzaparin an effective treatment for Superficial Venous Thrombosis?


A. Giannoukas

Customized Seal for Each Patient

With the Ovation Prime system, physicians create a customized seal by filling the graft's conformable O-rings with CustomSeal polymer.



Pre-operative illustration and CT image of aortic neck with significant calcium and thrombus



17 month follow-up illustration and CT image of aortic neck with sealing ring conforming to irregular surface, creating a custom seal

Sponsors-Acknowledgements

LIVE 2015 Directors sincerely thank the following companies for their financial support and substantial contribution to the realization of the symposium:

MAJOR SPONSORS



Bayer



Medtronic

SPONSORS

(in alphabetic order)



GE Healthcare



Pierre Fabre
FARMAKA S.A.



MAJOR SPONSORS



Bayer



Medtronic



Valiant™ Captivia™

THORACIC STENT GRAFT DELIVERY SYSTEM

NOW WITH
4MM PROXIMAL
FREEFLO TAPERS

A detailed view of the Valiant Captivia stent graft delivery system. It shows a blue and white handle with a control knob, connected to a long, thin catheter. A white, zig-zag patterned stent graft is being deployed from the catheter. The background is a bright yellow with abstract geometric shapes.

Confidence in Control

- Proximal FreeFlo Tapers help you treat more anatomies with confidence
- Over 2500 possible combinations*: Options to help you address a wide patient population†

*Data on file at Medtronic, Inc.
†LITVIN, WILSON, and Carvalhal et al studied the Valiant Stent Graft System

Medtronic Hellas S.A.
5, Ag. Varvaras str., 152 31 Halandri
Tel: 210 67.79.099, Fax: 210 67.79.399
www.medtronic.com

Innovating for life.



Xarelto[®]

rivaroxaban

10mg, 15mg & 20mg



L.GR.GM.: 10.2014.0384



Bayer

Κάτοχος της άδειας κυκλοφορίας:
Bayer Pharma AG, 13342 Berlin, Γερμανία
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ABEE, Σωρού
18-20, 151 25 Μαρούσι,
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Κύπρο: Novagem Ltd,
Τηλ.: 00357 22483858

Τμήμα Επιστημονικής Ενήμερωσης
Τηλ: +30 210 6187742, Fax: +30 210 6187522
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπίρωθης
για το Xarelto 15mg & 20mg



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,
Τηλ: 210 6039326 - 9, Fax: 210 6039300
ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα,
Τηλ: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ: 2310 459920 - 1, Fax: 2310 459269

Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη των
Χαρακτηριστικών του Προϊόντος που διατίθεται στο εκθετήριο

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Leading
Innovative
Vascular
Education

2016

Organized by:



Institute
of Vascular Diseases (IVD),
Greece



May 19-21
2016

Ioannina
GREECE

<http://www.live2016.gr>



LIVE 2016 Symposium
will be submitted to be approved
with CME credits by the EACCME of the UEMS